Original Article
Enoxaparin versus Unfractionated Heparin with Fibrinolysis for ST-Elevation Myocardial Infarction
N Engl J Med 2006; 354:1477-1488April 6, 2006
- Abstract
Background
Unfractionated heparin is often used as adjunctive therapy with fibrinolysis in patients with ST-elevation myocardial infarction. We compared a low-molecular-weight heparin, enoxaparin, with unfractionated heparin for this purpose.
Methods
We randomly assigned 20,506 patients with ST-elevation myocardial infarction who were scheduled to undergo fibrinolysis to receive enoxaparin throughout the index hospitalization or weight-based unfractionated heparin for at least 48 hours. The primary efficacy end point was death or nonfatal recurrent myocardial infarction through 30 days.
Results
The primary end point occurred in 12.0 percent of patients in the unfractionated heparin group and 9.9 percent of those in the enoxaparin group (17 percent reduction in relative risk, P<0.001). Nonfatal reinfarction occurred in 4.5 percent of the patients receiving unfractionated heparin and 3.0 percent of those receiving enoxaparin (33 percent reduction in relative risk, P<0.001); 7.5 percent of patients given unfractionated heparin died, as did 6.9 percent of those given enoxaparin (P=0.11). The composite of death, nonfatal reinfarction, or urgent revascularization occurred in 14.5 percent of patients given unfractionated heparin and 11.7 percent of those given enoxaparin (P<0.001); major bleeding occurred in 1.4 percent and 2.1 percent, respectively (P<0.001). The composite of death, nonfatal reinfarction, or nonfatal intracranial hemorrhage (a measure of net clinical benefit) occurred in 12.2 percent of patients given unfractionated heparin and 10.1 percent of those given enoxaparin (P<0.001).
Conclusions
In patients receiving fibrinolysis for ST-elevation myocardial infarction, treatment with enoxaparin throughout the index hospitalization is superior to treatment with unfractionated heparin for 48 hours but is associated with an increase in major bleeding episodes. These findings should be interpreted in the context of net clinical benefit. (ClinicalTrials.gov number, NCT00077792.)
Media in This Article
Figure 1
Cumulative Incidence of the Primary End Point (Panel A) and the Secondary End Point (Panel B).Figure 2
Relative Risks of and Absolute Event Rates for the Primary End Point at 30 Days in Various Subgroups.Article Activity
- Article
Fibrinolysis is the most common method of reperfusion used worldwide for patients with ST-elevation myocardial infarction. In addition to advocating that a fibrinolytic agent be combined with aspirin, contemporary guidelines recommend the routine administration of unfractionated heparin.1,2 Despite receiving a regimen of a fibrinolytic agent, aspirin, and unfractionated heparin, a substantial number of patients die or have another nonfatal myocardial infarction within one month after treatment.3-9 Prolonged intravenous infusions of unfractionated heparin have not been shown to prevent reocclusion after angiographically proven successful fibrinolysis, leading to the current recommendation to limit the duration of infusion to 48 hours.1,2 The use of unfractionated heparin requires frequent monitoring to adjust the infusion rate to maintain a therapeutic range of anticoagulation.10
The low-molecular-weight heparins are potential replacements for unfractionated heparin.11,12 As compared with unfractionated heparin, enoxaparin (Lovenox, Sanofi-Aventis) provides both a reliable level of anticoagulation without the need for therapeutic monitoring and relatively greater proximal inhibition of the coagulation cascade because it results in a ratio of anti–factor Xa to anti–factor IIa activity of 3.8:1.10 The Enoxaparin and Thrombolysis Reperfusion for Acute Myocardial Infarction Treatment (ExTRACT)–Thrombolysis in Myocardial Infarction (TIMI) 25 study was designed to compare enoxaparin and unfractionated heparin as adjunctive therapy for fibrinolysis in ST-elevation myocardial infarction.11 Because of the advantage offered by the ability to administer enoxaparin subcutaneously, we tested a strategy in which enoxaparin was administered for the duration of the index hospitalization, to decrease the risk of reocclusion of the infarct artery. Since enoxaparin reportedly increases the risk of bleeding in elderly patients,13 we devised a specific dosing regimen for patients 75 years of age or older and reduced the dose in patients of any age who had a clinically significant impairment in renal function.11
Methods
Patient Population
Between October 24, 2002, and October 1, 2005, 20,506 patients underwent randomization at 674 sites in 48 countries (see the Appendix). Eligible patients were at least 18 years of age, had at least 20 minutes of ischemic symptoms while at rest within 6 hours before randomization, had ST-segment elevation of at least 0.1 mV in two limb leads or of 0.2 mV in at least two contiguous precordial leads or had left bundle-branch block, and were scheduled to undergo fibrinolysis with streptokinase, tenecteplase, alteplase, or reteplase.11 Patients were ineligible if they had any of the following major exclusion criteria: cardiogenic shock, pericarditis, symptoms of aortic dissection, contraindications to fibrinolysis, receipt of a low-molecular-weight heparin within the prior eight hours, known renal insufficiency (defined by a serum creatinine level of greater than 220 μmol per liter [2.5 mg per deciliter] for men and greater than 175 μmol per liter [2.0 mg per deciliter] for women), or a life expectancy of less than 12 months.11
The protocol was approved by the local institutional review board at participating centers. Written informed consent was obtained from all patients in the intention-to-treat and safety populations, except for six, who provided oral informed consent.
Study Protocol
Patients were to receive, at the treating physician's discretion, streptokinase, tenecteplase, alteplase, or reteplase according to the manufacturers' instructions for the treatment of ST-elevation myocardial infarction. All patients were to receive 150 to 325 mg of aspirin in a nonenteric formulation orally or 500 mg intravenously unless they had received at least 325 mg of aspirin within the prior 24 hours. After the first 24 hours, maintenance therapy with 75 to 325 mg of aspirin once daily was to be administered orally for at least 30 days. Alternative antiplatelet agents such as clopidogrel could be used in patients with an allergy to aspirin, or they could be added to aspirin at the investigator's discretion, as part of the patient's treatment regimen.
Patients were randomly assigned in a 1:1 ratio to receive enoxaparin or unfractionated heparin with the use of a central, computerized system, according to the type of fibrinolytic agent. Study medication was to be administered in a double-blind fashion with the use of a double-dummy design between 15 minutes before and 30 minutes after the initiation of fibrinolytic therapy and was to occur within 30 minutes after randomization.
Unfractionated heparin (or matching placebo) was to be administered beginning with an intravenous bolus of 60 U per kilogram of body weight (maximum, 4000 U). The intravenous bolus was to be omitted for patients who received open-label unfractionated heparin (at least 4000 U) within three hours before randomization. Within 15 minutes after the intravenous bolus, an infusion of 12 U per kilogram per hour (initial maximum, 1000 U per hour) was begun. All monitoring of anticoagulation to adjust the dose of unfractionated heparin to maintain an activated partial-thromboplastin time of 1.5 to 2.0 times the control value was performed in a blinded fashion by personnel caring for the patient or in an unblinded fashion by a designated medical professional not involved in the patient's care.11 The intravenous infusion was to be given for at least 48 hours but could be continued for a longer period at the treating physician's discretion.
The enoxaparin dosing strategy was adjusted according to the patient's age and renal function. For patients younger than 75 years of age, enoxaparin (or matching placebo) was to be given as a fixed, 30-mg intravenous bolus followed 15 minutes later by a subcutaneous injection of 1.0 mg per kilogram, with injections administered every 12 hours. For patients at least 75 years of age, the intravenous bolus was eliminated and the subcutaneous dose was reduced to 0.75 mg per kilogram every 12 hours. For the first two subcutaneous injections, a maximum of 100 mg (for patients less than 75 years old) or 75 mg (for those at least 75 years old) was to be administered. To reduce the risk of bleeding, the intravenous bolus was to be omitted for patients who received open-label unfractionated heparin (at least 4000 U) within three hours before randomization. For patients with an estimated creatinine clearance of less than 30 ml per minute, the dose was to be modified to 1.0 mg per kilogram every 24 hours.11 The double-blind subcutaneous injections of enoxaparin or matching placebo were to continue until hospital discharge or for a maximum of eight days (whichever came first).
Although percutaneous coronary interventions could be performed at any time as rescue therapy for failed fibrinolysis or urgently, in response to an episode of recurrent myocardial ischemia or infarction, the protocol recommended the deferral of elective procedures for at least 48 hours after randomization. Patients undergoing percutaneous coronary interventions were to receive antithrombotic support with masked study drug, which could be discontinued after uncomplicated procedures at the discretion of the treating physician.11 Patients were monitored for clinical end points and adverse events during the index hospitalization and through day 30 (ascertained, day 31 to 38) in person or by telephone.
End Points
The primary efficacy end point was the composite of death from any cause or nonfatal recurrent myocardial infarction in the first 30 days after randomization. The main secondary end point was the composite of death from any cause, nonfatal reinfarction, or recurrent myocardial ischemia leading to urgent revascularization in the first 30 days. An additional secondary end point (net clinical benefit) was the composite of death from any cause, nonfatal reinfarction, or nonfatal disabling stroke. We included two other prespecified net-clinical-benefit end points: first, death, nonfatal recurrent myocardial infarction, or a nonfatal episode of major bleeding; and second, death, nonfatal myocardial infarction, or nonfatal intracranial hemorrhage. Bleeding was classified according to the TIMI criteria.11 All ischemic and clinically significant bleeding events were adjudicated in a blinded fashion by an independent clinical-events committee using prespecified definitions.11
Statistical Analysis
The trial was designed to have a statistical power of at least 90 percent to detect a 13 percent relative risk reduction in the primary end point with enoxaparin and used an event-driven approach. We estimated that randomization of approximately 21,000 patients would be required to yield the target of 2080 events.
All efficacy comparisons were analyzed according to the intention-to-treat principle. The analysis of the primary efficacy end point included all primary efficacy end points known to have occurred through 30 days after randomization and in the database that was locked on January 27, 2006. We prospectively planned to summarize events occurring after day 30 that were identified on the visit at day 30 (range, day 31 to 38) in a 6-month study report. The chi-square test was used to compare the primary and secondary end points in the two treatment groups. A log-rank test was also performed. All safety analyses were performed according to the treatment actually received by the patient.
An independent data and safety monitoring board monitored efficacy and safety. Prespecified interim analyses for efficacy and safety were conducted after approximately 25 percent, 50 percent, and 75 percent of the total targeted number of primary end-point events had occurred, according to the Lan–DeMets type of O'Brien–Fleming stopping boundary. The critical two-sided P value for the final analysis of the primary efficacy end point, after correction for interim analyses, was 0.043. A P value of less than 0.05 was the threshold for nominal significance for all other end points.
The trial was designed as a collaborative effort between members of the steering committee and the sponsor, Sanofi-Aventis. The data were collected by a contract research organization (Quintiles). The raw database was provided by the sponsor to members of the TIMI Study Group. The prespecified and exploratory analyses were carried out independently by the TIMI Study Group (whose members wrote this report and take responsibility for the data) as well as the sponsor.
Results
A total of 20,506 patients underwent randomization, of whom 20,479 were included in the intention-to-treat population; they were well matched for baseline characteristics (Table 1Table 1
Baseline Characteristics of the Patients.). The profile of their characteristics was similar to that seen in contemporary trials of interventions for ST-elevation myocardial infarction. The treatment groups were well matched with respect to concomitant therapy with other guideline-recommended treatments, such as aspirin, beta-blockers, and inhibitors of the renin–angiotensin system; the majority of patients received all these treatments.A fibrinolytic agent was administered to 99.7 percent of patients, with 79.5 percent receiving a fibrin-specific agent and 20.2 percent receiving streptokinase (Table 1). The median time from the onset of symptoms to the start of fibrinolytic therapy was 3.2 hours.
A total of 15.8 percent of patients had received open-label unfractionated heparin in the three hours preceding randomization, and 0.5 percent had received low-molecular-weight heparin in the seven days preceding randomization (Table 1). Study drug was administered in a blinded fashion to 99.2 percent of patients, with 97.1 percent receiving it within 30 minutes after the start of fibrinolytic therapy.
As anticipated by the protocol design, treatment with enoxaparin lasted a median of 7.0 days (defined as 24-hour intervals after randomization) (interquartile range, 4.5 to 7.5; 90th percentile, 7.5) and treatment with unfractionated heparin lasted a median of 2.0 days (interquartile range, 2.0 to 2.2; 90th percentile, 3.2). The median duration of hospitalization for the study population was 10 days (interquartile range, 7 to 17). The qualifying infarction was treated with medical therapy alone in 74.3 percent of patients, a percutaneous coronary intervention in 23.0 percent (as rescue therapy in 2.8 percent and as an urgent or elective procedure in 20.2 percent), and coronary-artery bypass surgery in 2.8 percent of patients.
Efficacy End Points
The primary end point was ascertained at 30 days in all but three patients in the intention-to-treat population. The rate of the primary efficacy end point (death or nonfatal myocardial infarction) was 9.9 percent in the enoxaparin group, as compared with 12.0 percent in the unfractionated heparin group (17 percent reduction in the relative risk, P<0.001) (Table 2Table 2
Efficacy Outcomes. and Figure 1AFigure 1Cumulative Incidence of the Primary End Point (Panel A) and the Secondary End Point (Panel B).). The beneficial effect of enoxaparin on the primary end point was consistent across key prespecified subgroups (Figure 2Figure 2Relative Risks of and Absolute Event Rates for the Primary End Point at 30 Days in Various Subgroups.). In addition, there was a significant treatment benefit of enoxaparin, as compared with unfractionated heparin, in patients who underwent percutaneous coronary intervention within 30 days after randomization (23 percent reduction in relative risk) or who were treated medically (16 percent reduction in relative risk, P=0.33 for interaction). The treatment benefits of enoxaparin, evident for a number of efficacy outcomes, emerged at 48 hours, at which time there was a 33 percent reduction in the relative risk of nonfatal myocardial infarction, as compared with treatment with unfractionated heparin (P=0.002) (Table 2).At 30 days, the mortality rate was 7.5 percent in the unfractionated heparin group, as compared with 6.9 percent in the enoxaparin group (P=0.11) (Table 2). Enoxaparin significantly reduced the rate of recurrent nonfatal myocardial infarction (3.0 percent, vs. 4.5 percent in the unfractionated heparin group; 33 percent reduction in the relative risk; P<0.001) (Table 2). Episodes of recurrent myocardial ischemia leading to urgent revascularization were significantly reduced, from 2.8 percent in the unfractionated heparin group to 2.1 percent in the enoxaparin group (P<0.001) (Table 2). As compared with unfractionated heparin, enoxaparin also significantly reduced the incidence of the main secondary end point of death, nonfatal myocardial infarction, or urgent revascularization (11.7 percent vs. 14.5 percent, P<0.001) (Table 2 and Figure 1B).
Safety End Points
The rates of TIMI major bleeding (including intracranial hemorrhage) at 30 days were 1.4 percent in the unfractionated heparin group and 2.1 percent in the enoxaparin group (absolute increase of 0.7 percentage point and 53 percent increase in the relative risk, P<0.001) (Table 3Table 3
Safety Outcomes.). The rates of intracranial hemorrhage were 0.7 percent in the unfractionated heparin group and 0.8 percent in the enoxaparin group (P=0.14). The respective rates of minor bleeding and the composite of major or minor bleeding were 0.8 and 1.5 percentage points higher in the enoxaparin group than in the group given unfractionated heparin (relative risk, 1.41 and 1.47, respectively) (Table 3).Net Clinical Benefit
The rates of all three prespecified net-clinical-benefit composite end points were significantly lower at 30 days in the enoxaparin group than in the unfractionated heparin group (Table 4Table 4
Net Clinical Benefit at 30 Days.). Enoxaparin had a similar, beneficial effect on these end points, which are composites of efficacy and different aspects of safety (nonfatal disabling stroke, nonfatal major bleeding, and nonfatal intracranial hemorrhage). The range of reductions in the absolute event rates was 1.8 to 2.2 percentage points, corresponding to reductions in the relative risk of 14 to 18 percent (P<0.001 for all comparisons).Discussion
Our results demonstrate that a strategy of administering enoxaparin throughout the index hospitalization is superior to the current strategy of administering unfractionated heparin for 48 hours as adjunctive antithrombin therapy for patients with ST-elevation myocardial infarction who undergo pharmacologic reperfusion with a fibrinolytic agent. Although antithrombin agents have not been reported to enhance initial clot lysis, their use as part of a pharmacologic reperfusion regimen is associated with a higher rate of patency of the infarct artery hours to days after initial fibrinolytic therapy and a lower rate of recurrent myocardial infarction.14-16 After initially successful fibrinolysis, reocclusion of the infarct artery is associated with a near tripling of mortality.17-19 The risk of reocclusion is related to the underlying degree of stenosis and the residual thrombus.20-22
Three factors may have contributed to the treatment differences we observed: a superior antithrombotic effect of enoxaparin, a longer duration of treatment with enoxaparin, and possibly, a rebound increase in thrombotic events after the discontinuation of unfractionated heparin, as suggested by the shape of the curves in Figure 1. We are unable to determine definitively the relative contributions of each of these factors to the results observed.
The significant 33 percent reduction in the relative risk of myocardial reinfarction at 30 days with enoxaparin suggests that the antithrombotic effect of this agent is superior to that achieved with the currently recommended regimen of unfractionated heparin. We also observed a 26 percent reduction in the need for urgent revascularization at 30 days in the enoxaparin group (Table 2). The superior antithrombotic effect of enoxaparin may be explained, in part, by its greater ratio of anti–factor Xa to anti–factor IIa activity, since the inhibition of a single molecule of factor Xa inhibits the downstream production of many thrombin molecules.10,23
The convenience of the subcutaneous route of administration was a factor in our decision to test a strategy of administering enoxaparin for the duration of the index hospitalization. Extended treatment with enoxaparin most likely contributed to a more sustained antithrombotic effect. It is notable that the rate of the main secondary end point of death, nonfatal myocardial infarction, or urgent revascularization was significantly lower in the enoxaparin group than in the unfractionated heparin group within 48 hours. Previous work failed to show that the infusion of unfractionated heparin for more than 48 hours prevents reocclusion of successfully reperfused infarct arteries in patients with ST-elevation myocardial infarction.1,2,24 Furthermore, no strategies for dealing with the possibility of rebound after the discontinuation of unfractionated heparin have been rigorously examined, and rebound may occur after treatment with unfractionated heparin regardless of the duration of the infusion.10
There was no significant increase in the rate of intracranial hemorrhage with enoxaparin therapy. There was, however, a significant increase in episodes of major bleeding. Although comparisons across trials are difficult because of the possible effect of differences in definitions of bleeding, the rates of major bleeding in both treatment groups were lower than those reported in a prior meta-analysis (in which the in-hospital rate of major bleeding was 3.3 percent with enoxaparin and 2.5 percent with unfractionated heparin).12 The low rate of use of open-label unfractionated heparin before randomization, the use of conservative dosing strategies, and avoidance of double anticoagulation through the use of masked study drug to support percutaneous coronary interventions may have contributed to the low bleeding rates we observed.
Our findings indicate that treatment with enoxaparin throughout the index hospitalization for ST-elevation myocardial infarction is superior to the current strategy of infusing unfractionated heparin for 48 hours as adjunctive antithrombin therapy to fibrinolysis. For every 1000 patients treated with the enoxaparin strategy, there would be 15 fewer nonfatal reinfarctions, 7 fewer episodes of urgent revascularization, and 6 fewer deaths, at the cost of 4 additional episodes of nonfatal major bleeding (with no increase in the number of nonfatal intracranial hemorrhages). It is our judgment that despite the increase in episodes of major bleeding, the early and sustained reduction in ischemic events and the balance of efficacy and safety, as assessed by three net-clinical-benefit end points, demonstrate the advantage of the regimen of enoxaparin over 48 hours of unfractionated heparin as the adjunctive antithrombin regimen to support fibrinolysis.
Supported by a research grant from Sanofi-Aventis to the TIMI Study Group.
Drs. Antman, Morrow, López-Sendón, White, Fox, and Braunwald report having received research grant support from Sanofi-Aventis, having received lecture fees from Sanofi-Aventis, and having served on paid advisory boards for Sanofi-Aventis. Drs. Ruda, Sadowski, Budaj, and Guneri and Ms. McCabe and Ms. Murphy report having received research grant support from Sanofi-Aventis. Dr. Jiang is an employee of Sanofi-Aventis. No other potential conflict of interest relevant to this article was reported.
This article was published at www.nejm.org on March 14, 2006.
Source Information
From the Thrombolysis in Myocardial Infarction (TIMI) Study Group, Cardiovascular Division, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston (E.M.A., D.A.M., C.H.M., S.A.M., E.B.); the Department of Emergency Cardiology, Cardiology Research Center, Moscow (M.R.); the National Institute of Cardiology (Z.S.) and the Postgraduate Medical School, Department of Cardiology, Grochowski Hospital (A.B.) — both in Warsaw, Poland; Hospital Universitario La Paz, Madrid (J.L.L.-S.); Dokuz Eylul Universitesi, Izmir, Turkey (S.G.); International Clinical Development, Sanofi-Aventis, Bridgewater, N.J. (F.J.); Green Lane Cardiovascular Service, Auckland City Hospital, Auckland, New Zealand (H.D.W.); and the University of Edinburgh, Cardiovascular Research, Edinburgh (K.A.A.F.).
Address reprint requests to Dr. Antman at the TIMI Study Group, Cardiovascular Division, Brigham and Women's Hospital, 75 Francis St., Boston, MA 02115, or at eantman@rics.bwh.harvard.edu.
The participants in the Enoxaparin and Thrombolysis Reperfusion for Acute Myocardial Infarction Treatment (ExTRACT)–Thrombolysis in Myocardial Infarction (TIMI) 25 Study are listed in the Appendix.
Appendix
The participants in the ExTRACT–TIMI 25 Study are as follows: TIMI Study Group, Brigham and Women's Hospital, Boston — E. Braunwald (study chair), E.M. Antman (principal investigator), C. McCabe, D.A. Morrow, S.A. Murphy, S. McHale; Sanofi-Aventis, Bridgewater, N.J. (sponsor) — F. Jiang, C. Gaudin, P. Chew, L. Cui, L. Teoh, S. Fontecave, J. Cortez, K. Giordano, R. Merino, R. Smith, T. Luo, S. Martin, G. Guironnet, C. Akhoundi, L. Siffre, C. Nouck-A-Nwal; Data Coordinating Center — K. Long (Quintiles); Centralized Randomization — R. Luthra, K. Hatfield (ClinPhone); Data Management for Activated Partial-Thromboplastin Time — M. Sabbe (Covance); Executive Committee — E. Braunwald, H. White, K.A.A. Fox; Steering Committee — E. Braunwald, E.M. Antman, C. McCabe, D.A. Morrow, S.A. Murphy, S. McHale; Argentina — E. Gurfinkel; Australia — P. Aylward; Austria — K. Huber; Belarus — L. Polonetsky; Belgium — J. Col; Brazil — J.C. Nicolau; Romania — M. Dorobantu; Bulgaria — N. Gotcheva; Canada — A. Turpie, P. Theroux, A. Langer; Chile — R. Corbalan; China — R. Gao; Croatia — M. Bergovec; Estonia — J. Voitk; France — G. Montalescot; Germany — D. Gulba; Hong Kong, China — K.S. Woo; Hungary — E. Ostor; Israel — H. Hod; Italy — D. Ardissino; Korea — K.-B. Seung; Latvia — U. Kalnins; Malaysia — D. Robaayah Zambahari; Mexico — A. Garcia Castillo; the Netherlands — P. Molhoek, F. Verheught; New Zealand — H. White; Norway — K. Dickstein; Poland — Z. Sadowski, A. Budaj; Portugal — J. Morais; Russia — M. Ruda, S. Varshavsky; Singapore — H. Cheem; Slovakia — T. Duris; South Africa — A. Dalby; Spain — J. López-Sendón; Sweden — S. Agewall; Switzerland — M. Pfisterer; Turkey — S. Guneri; Ukraine — A. Parkhomenko; United Kingdom — A.J. Jacob, K.A.A. Fox; United States — J. Alpert, R. Califf, M. Cohen; Data and Safety Monitoring Board: F. Van de Werf (chair), D. DeMets, D. Julian, J. Rouleau, J. Ward Kennedy, J. Anderson, K. Lee, S. Sapp; Clinical Centers and Principal Investigators (in descending order of patient enrollment) — Russian Federation: V. Shulman, V. Lusov, A. Vishnevskiy, A. Duda, P. Dovgalevsky, V. Mkrtchian, M. Boyarkin, O. Barbarash, Y. Gabinsky, Y. Shvarts, D. Belenky, S. Shalaev, V. Yakusevich, M. Glezer, V. Kostenko, V. Markov, M. Ruda, I. Bokarev, S. Tereschenko, S. Yakushin, O. Khrustalev, V. Moiseev, V. Barbarich, O. Lapin, N. Gratsiansky, M. Baluda, V. Shmyrova, A. Panov, G. Aroutiounov, R. Stryuk, L. Katelnitskaya, D. Zateyschikov, E. Volkova, V. Tyrenko, A. Shpektor, S. Boldueva, Y. Grinstein, G. Zalevsky, A. Petrov, G. Storozhakov, M. Arkhipov, N. Zubanov; Poland: A. Drzewiecki, J. Kopaczewski, M. Krzeminska-Pakula, M. Bronisz, A. Gieroba, K. Jaworska, M. Ogorek, K. Zmudka, T. Kawka-Urbanek, K. Wrabec, E. Zinka, P. Kolodziej, J. Tarchalski, M. Ujda, M. Skura, P. Burduk, K. Kuc, J. Kuzniar, J. Mormul, M. Janion, T. Czerski, W. Ruminski, P. Achremeczyk, A. Lugowski, D. Wojciechowski, A. Kleinrok, M. Trusz-Gluza, M. Goszczynska, R. Sciborski, R. Szelemej; Spain: J.A. Cambronero, J. Froufe, J. Ortega, S. Nicolas, J. Blanco Varela, H. Pérez Hernández, L. Ramos, J. Martín, P. Pabón Osuna, A.J. Montón, R. Claramonte, P. Marco, A. Loma Osorio, M. Ruano, E. Esplugas, A. Ricart, R. Rubio Sanz, J. Torres Ruiz, I. Antorrena-Maranda, M. Fiol Sala, J. Nava, A. Lesmes, G. Pérez Planelles, V. López, P. Galdos, M. Piqué, V. Valle, V. Valentín, J. Bassaganyas, A. Pérez Garrido, J. Masip, J. Merino, R. Fernández-Fernández, A. Carrillo, R. Vicho, J. Bayón, J. San José, J. Bruguera, F. Taboada, A. Rovira, J. Arias, F. Bellot, F. Ortiz; Turkey: E. Diker, A. Oguzhan, M. Yesil, S. Guneri, M. Demirtas, C. Turkoglu, T. Kurum, A. Aydinlar, B. Timuralp, F. Ertas, A. Vural, H. Senocak, S. Celik, H. Muderrisoglu, M. Aksoy, A. Cengel, N. Cam, G. Cin, D. Ural, M. Baltali; Israel: N. Roguin, O. Kracoff, B. Lewis, T. Rosenfeld, Y. Rozenman, A. Roth, D. David, L. Reisin, E. Kaluski, S. Matetzky, H. Hammerman, S. Meisel, D. Zahger, J. Balkin; Ukraine: I. Krayz, O. Koval, K. Amosova, V. Tseluyko, A. Parhomenko, O. Karpenko, A. Fainyk, V. Netyazhenko, V. Syvolap, Y. Dykun, L. Kononenko, B. Goloborodko; India: N.K. Reddy, J.P.S. Sawhney, P.K. Grant, S.S. Ramesh, J.S. Bhuvaneshwaran, B. Ramesh Babu, V.K. Puri, T. Alexander, A. Mullasari, T. Nair, S.S. Iyengar, R.P.S. Bharadwaj, K. Parikh, S. Rane; the Netherlands: G.C.M. Linssen, P. Bendermacher, E. Van Nes, A.G. Boehmer, M. Kofflard, B. Hamer, M.C.G. Daniels, A. Derks, R.F. Veldkamp, A.H. Liem, R.M. Tjon Joe Gin, M. Van Hessen, J. Tans, W.J.T. Jap Tjeon San, P.R.M. Van Dijkman, M.P. Freericks, P. Zijnen, H.J.M. Thijssen, A. Withagen, P.R. Nierop, J.H.M. Schreur, M. Van Der Linden, A.H. Herweijer, H.A. Werner, B.J. Van Den Berg, P. Van Rossum, G.J. Van Beek, R.M. Robles De Medina, P. Van Der Meer, L.H. Takens, P. Dunselman, R. Ciampricotti, T. Van Loenhout; United Kingdom: A. Jacob, R. Cowell, C. Francis, M. Brack, R. Senior, P.R. Wilkinson, I.R. Starkey, J. Adgey, K.A.A. Fox, R. Wray, N. Patel, R. Ahmad, M. Farrer, S. Talwar, N. Herity, K. Jennings, R. Aggarwal, B. McClements, M. Al-Khafaji, J. Forfar, A. Pell, J. Rowley, A. Bridges, S. Saltissi, J.D. Stephens, D. Hackett, S. Lindsay, W. Grabau, A. Alwail, A. Rozkovec, A. Rae, C. Lawson, M. Pye, K. Morris, A.O. Molajo, M. Hargreaves, R. Mansfield, J. Doig, P. Lewis, A. Nasser, H. Papaconstantinou, B. Vallance, R. Andrews, M. Been, S. Virk, P. Wong, R. Wilcox, P. Stubbs, R. Grocott-Mason, S. Gupta, D. Bruce, B. Saeed, J. Dhawan, C. Plummer, G. Lip, I. Hudson, P.R. Walker, T. Mathew, S.J. Hutchison, W.J. Penny, M. Pitt, P. Weissberg, I. Findlay, S. Cross, L. Bhatia; Italy: G. Corsini, A. Vetrano, P. Terrosu, V. Ciconte, C. Astarita, O. Silvestri, L. Fattore, G. Ruggeri, A. Fiscella, M. Comito, M. Barbiero, F. Miccoli, M.G. Carmina, G. Giorgi, D. Banda, A. Capucci, I. De Luca, S. Severi, F. Cariello, M. Brignole, A. Grieco, M. Di Biase, R. Evola, A. Rolli, T. Morgera, P. Maras, S. Ricci, M. Orlandi, B. Tuccillo, M. Onofri, F. Melandri, R. Delfino, F. Arrigo, L. Vasquez, A. Bongo, C. Cernigliaro, P. Bellotti, S. Pirelli, C. Barletta, E. Renaldini, N. Ciampani, G. Altamura, S. Domenicucci, F. Tartagni; Romania: M. Cinteza, M. Vintila, M. Dorobantu, C. Georgescu, D. Ionescu, C.F. Pop, R. Capalneanu, C. Macarie, R. Mariana; Bulgaria: S. Milanov, A. Popov, M. Tzekova, N. Penkov, B. Chompalova, V. Hergeldjieva, M. Grigorov, S. Denchev, H. Kojuharov, I. Perchev, N. Gotcheva; Hungary: S. Timar, Z. Kovacs, M. Sereg, A. Katona, C. Toth, Z. Bogdan, A. Matoltsy, S. Amer, I. Horvath, A. Kovacs, F. Poor, E. Kalo, C. Dezsi, I. Inczeffy, I. Preda; New Zealand: D. Friedlander, A. Hamer, H. Hart, J. Hedley, R. Luke, T. O'Meeghan, R. Rankin, D. Scott, A. Aitken, J. Tisch, H. White, G. Wilkins, I. Ternouth, M. Hills; Chile: R. Lamich, F. Gutierrez, O. Pedemonte, G. Arriagada, F. Albornoz, S. Urgarte, F. Cardenas, J. Escobar, C. Bugueno, E. Chavez, G. Illanes, R. Corbalan, P. Sanhueza; Brazil: P. Rossi, J. Miranda Abrantes, O. Dutra, C. Gun, L. Maia, J. Quinaglia, E. Silva, V. Golin, A. Timermann, J. Marin Neto, L.C. Bodanese, O. Coelho, G. Greque, P. Nogueira, J. Braga, A. Rabelo Alves, Jr., A. Carvalho, C. Serrano, J. Saraiva, M. Baptista Filho, D. De Albuquerque; China: Y. Han, S. Lv, S. Jia, Q. Wu, X. Yang, H. Ma, B. Sun, M. Wei, D. Hu, B. Zhao, W. Gao, J. Ge, W. Fan, J. Chen, Q. Dang, R. Gao, Y. Huo, B. Yu, W. Zhu, L. Gai, W. Li, X. Li, X. Zhou, G. Zhu; Argentina: S. Macin, G. Bortman, A. Caccavo, M. Halac, J. Beloscar, O. Caruso, E. Gurfinkel, S. Chekherdemian, H. Luquez, D. Agranatti, R. Ahuad Guerrero, R. Badra, M. Hominal, H. Torres, A. Campo, C. Pellegrini, L. Girotti, M. Litvak Bruno, I. Chaves, C. Estrada, M. Russo, J. Bono, R. Perez de la Hoz; Slovakia: V. Spisak, J. Kmec, T. Duris, A. Banikova, V. Macek, J. Hasilla, O. Herman; South Africa: J. Bayat, I. Ebrahim, A. Doubell, R. Naidu, P. Blomerus, F. Maritz, L. Van Zyl, L. Steingo, A. Dalby, T. Mabin, E. Lloyd, R. Routier, J. Steyn, D. Duncan, A. Da Silva, T. Venter, J. Patel, M. Seeber; Australia: J. Counsell, D. Henderson, C. Hii, J. Waites, P. Carroll, M. Schoeman, B. Singh, A. Whelan, P. Thompson, G. Aroney, D. Chew, D. Cross, P. Boyd, J. Strickland, J. Horowitz, S. David, S. Coverdale, T. Smyth; Mexico: U. Juarez, G. Lopez-Ramos, A. Nacoud, A. Mireles, J. Carrillo, I. Hernandez, F. Petersen, A. Garcia, M. Zuniga, P. Hinojosa-Pineda; Republic of Korea: J.H. Yoon, S.J. Kim, M.H. Jeong, K.B. Seung, Y.J. Kim, K.Y. Chang, K.S. Park, H.M. Kwon, E.J. Kim, S.C. Chae, W.S. Chung, M.Y. Lee, B.H. Oh, M.C. Cho; Croatia: K. Catipovic, P. Samardzic, A. Jovic, M. Padovan, B. Jaksic, D. Trsinski, G. Milicevic; Greece: J. Nanas, A. Zacharoulis, T. Apostolou, E. Papasteriadis, D. Hatseras, F. Triposkiadis, T. Kolettis, G. Louridas, V. Votteas, C. Papadopoulos, C. Stefanadis, P. Vardas; Germany: W. Leupolz, D. Buchholz, J. Epping, R. Zotz, B. Pfaffenbach, T. Dorsel, E. Eggers, G. Mertes, J. Ontyd, G. Lockert, B. Linder, R.D. Beythien, A. Klamann, G. Claus, P. Gaudron, T. Heyer, V. Hossmann, D. Gulba; Canada: P. Tan, M. Heffernan, R.K. Bhargava, W. Hui, L. Winkler, M. Senaratne, D. Kincade, J. Javier, S. Vizel, J. Graham, J. Stimac, D. Fitchett, S. Pallie, P. Smylie, M. Shuster; Thailand: A. Sukonthasarn, P. Sritara, D. Tresukosol, W. Buddhari, C. Piamsomboon; Belgium: D. El Allaf, A. De Meester, F. Foret, R. Popeye, F. Marenne, B. Pirenne, F. De Leener; Estonia: J. Voitk, V. Vahula, A. Reinold; Malaysia: S. Hian, R. Zambahari, W.P. Chong, J. Sinnadurai, C.Y. Lee, K. Yusoff, P. Mahadasa; Portugal: A. Aleixo, M.A. Pereira, L. Bernardino, M.V. Gomes, L. Martins, M.G. Silva, I. Moreira, L. Gomes, J. Puig, J.A. Santos; Austria: K. Huber, E. Grafl, A. Dalos, W. Schellnegger, G. Puhr, B. Bauer, H. Pristautz, P. Bratusch-Marrain, G. Gaul, H. Frank, A. Hartweger; Sweden: V. Roussine, S. Agewall, M. Lycksell, L. Lundkvist, S. Stalnacke, C. Stafberg, D. Hagstrom; Switzerland: H. Zender, T. Moccetti, A. Gallino, A. Pagnamenta, H.P. Voegelin, P. Ballmer; Belarus: L. Polonetsky, N. Soroka, A. Mrochak, A. Bulgak; United States: E. Lader, J. Gelormini, G. Miller, B. Patel, H. Morse, H. Chandna, C. Boylan, R. Morris, H. Mueller; Lithuania: V. Jokas, J. Brazdzionyte, B. Petrauskiene; Norway: T. Graven, A. Dimmen, T.M. Omland, F. Erchinger, T.I. Stakkevold; Latvia: G. Dormidontova, U. Kalnins, M. Keisa; Lebanon: S. Lawand, R. Kassab, A. Abchi; Singapore: Q.W. Yong, H.C. Tan; Finland: S. Voutilainen, K. Peuhkurinen, M. Huttunen, S. Utriainen; Uruguay: F. Di Leoni, J. Patriti, S. Bentancurt, A. Cataldo; Ireland: K. Daly, M. Conway, H. McCann, D. Mulcahy; Hong Kong, China: W.H. Chen, S.K. Kwong; Jordan: M. Nemri; France: N. Benazza.
- References
References
1
Antman EM, Anbe DT, Armstrong PW, et al. ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1999 Guidelines for the Management of Patients With Acute Myocardial Infarction). Bethesda, Md.: American College of Cardiology Foundation, 2004. (Accessed March 13, 2006, at http://www.acc.org/clinical/guidelines/stemi/index.pdf.)
2
Van de Werf F ,Ardissino D ,Betriu A , et al. Management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J 2003;24:28-66
CrossRef | Web of Science | Medline3
Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico
Web of Science | Medline4
ISIS-3 (Third International Study of Infarct Survival) Collaborative Group
CrossRef | Web of Science | Medline5
The GUSTO Investigators
Full Text | Web of Science | Medline6
The Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO) IIb Investigators
Full Text | Web of Science | Medline7
Antman EM . Hirudin in acute myocardial infarction: Thrombolysis and Thrombin Inhibition in Myocardial Infarction (TIMI) 9B trial. Circulation 1996;94:911-921
Web of Science | Medline8
The Continuous Infusion versus Double-Bolus Administration of Alteplase (COBALT) Investigators
Full Text | Web of Science | Medline9
The Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO III) Investigators
Full Text | Web of Science | Medline10
Antman EM . The search for replacements for unfractionated heparin. Circulation 2001;103:2310-2314
Web of Science | Medline11
Antman EM ,Morrow DA ,McCabe CH , et al. Enoxaparin versus unfractionated heparin as antithrombin therapy in patients receiving fibrinolysis for ST-elevation myocardial infarction: design and rationale for the Enoxaparin and Thrombolysis Reperfusion for Acute Myocardial Infarction Treatment-Thrombolysis In Myocardial Infarction study 25 (ExTRACT-TIMI 25). Am Heart J 2005;149:217-226
CrossRef | Web of Science | Medline12
Eikelboom JW ,Quinlan DJ ,Mehta SR ,Turpie AG ,Menown IB ,Yusuf S . Unfractionated and low-molecular-weight heparin as adjuncts to thrombolysis in aspirin-treated patients with ST-elevation acute myocardial infarction: a meta-analysis of the randomized trials. Circulation 2005;112:3855-3867
CrossRef | Web of Science | Medline13
Wallentin L ,Goldstein P ,Armstrong PW , et al. Efficacy and safety of tenecteplase in combination with the low-molecular-weight heparin enoxaparin or unfractionated heparin in the prehospital setting: the Assessment of the Safety and Efficacy of a New Thrombolytic Regimen (ASSENT)-3 PLUS randomized trial in acute myocardial infarction. Circulation 2003;108:135-142
CrossRef | Web of Science | Medline14
Topol EJ ,George BS ,Kereiakes DJ , et al. A randomized controlled trial of intravenous tissue plasminogen activator and early intravenous heparin in acute myocardial infarction. Circulation 1989;79:281-286
CrossRef | Web of Science | Medline15
Hsia J ,Hamilton WP ,Kleiman N ,Roberts R ,Chaitman BR ,Ross AM . A comparison between heparin and low-dose aspirin as adjunctive therapy with tissue plasminogen activator for acute myocardial infarction. N Engl J Med 1990;323:1433-1437
Full Text | Web of Science | Medline16
de Bono DP ,Simoons ML ,Tijssen J , et al. Effect of early intravenous heparin on coronary patency, infarct size, and bleeding complications after alteplase thrombolysis: results of a randomised double blind European Cooperative Study Group trial. Br Heart J 1992;67:122-128
CrossRef | Web of Science | Medline17
Mueller HS ,Forman SA ,Menegus MA ,Cohen LS ,Knatterud GL ,Braunwald E . Prognostic significance of nonfatal reinfarction during 3-year follow-up: results of the Thrombolysis in Myocardial Infarction (TIMI) phase II clinical trial. J Am Coll Cardiol 1995;26:900-907
CrossRef | Web of Science | Medline18
Ohman EM ,Califf RM ,Topol EJ , et al. Consequences of reocclusion after successful reperfusion therapy in acute myocardial infarction. Circulation 1990;82:781-791
CrossRef | Web of Science | Medline19
Gibson CM ,Karha J ,Murphy SA , et al. Early and long-term clinical outcomes associated with reinfarction following fibrinolytic administration in the Thrombolysis in Myocardial Infarction trials. J Am Coll Cardiol 2003;42:7-16
CrossRef | Web of Science | Medline20
Gash AK ,Spann JF ,Sherry S , et al. Factors influencing reocclusion after coronary thrombolysis for acute myocardial infarction. Am J Cardiol 1986;57:175-177
CrossRef | Web of Science | Medline21
Gulba DC ,Barthels M ,Westhoff-Bleck M , et al. Increased thrombin levels during thrombolytic therapy in acute myocardial infarction: relevance for the success of therapy. Circulation 1991;83:937-944
Web of Science | Medline22
Harrison DG ,Ferguson DW ,Collins SM , et al. Rethrombosis after reperfusion with streptokinase: importance of geometry of residual lesions. Circulation 1984;69:991-999
CrossRef | Web of Science | Medline23
Weitz JI . Low-molecular-weight heparins. N Engl J Med 1997;337:688-698[Erratum, N Engl J Med 1997;337:1567.]
Full Text | Web of Science | Medline24
Thompson PL ,Aylward PE ,Federman J , et al. A randomized comparison of intravenous heparin with oral aspirin and dipyridamole 24 hours after recombinant tissue-type plasminogen activator for acute myocardial infarction. Circulation 1991;83:1534-1542
Web of Science | Medline
- Citing Articles (203)
Citing Articles
1
Jeffrey C. Trost, Richard A. Lange. (2012) Treatment of acute coronary syndrome. Critical Care Medicine 40:6, 1939-1945
CrossRef2
S. Michael Gharacholou, Brenda J. Larson, Christian C. Zuver, Ryan J. Wubben, Giorgio Gimelli, Amish N. Raval. (2012) Pre PCI hospital antithrombotic therapy for ST elevation myocardial infarction: striving for consensus. Journal of Thrombosis and Thrombolysis
CrossRef3
Jaime Latour-Pérez, Eva de-Miguel-Balsa. (2012) Cost Effectiveness of Anticoagulation in Acute Coronary Syndromes. PharmacoEconomics 30:4, 303-321
CrossRef4
Tudor D Vagaonescu, George Dangas. (2012) Invasive management of the acute coronary syndromes. Interventional Cardiology 4:2, 279-285
CrossRef5
Frans Van de Werf, Diego Ardissino, Héctor Bueno, Jean-Philippe Collet, Anthony Gershlick, Philippe Kolh, Steen Dalby Kristensen, Sigmund Silber, Freek Verheugt, Wojtek Wojakowski. (2012) Acute coronary syndromes: considerations for improved acceptance and implementation of management guidelines. Expert Review of Cardiovascular Therapy 10:4, 489-503
CrossRef6
S. Farhan, I. Tentzeris, M.K. Freynhofer, B. Vogel, K. Huber. (2012) Antithrombotic therapy in patients with acute coronary syndrome and diabetes mellitus. Herz
CrossRef7
Martha Gulati, Leslee J. Shaw, C. Noel Bairey Merz. (2012) Myocardial Ischemia in Women: Lessons From the NHLBI WISE Study. Clinical Cardiology 35:3, 141-148
CrossRef8
Robert C. Welsh, Cynthia M. Westerhout, Christopher E. Buller, Blair O’Neill, Phillip Gordon, Paul W. Armstrong. (2012) Anticoagulation after subcutaneous enoxaparin is time sensitive in STEMI patients treated with tenecteplase. Journal of Thrombosis and Thrombolysis
CrossRef9
Shahar Lavi, Warren J. Cantor, Amparo Casanova, Mary K. Tan, Andrew T. Yan, Vladimír Džavík, David Fitchett, Eric A. Cohen, Bjug Borgundvaag, Michael Heffernan, John Ducas, Shaun G. Goodman. (2012) Efficacy and safety of enoxaparin compared with unfractionated heparin in the pharmacoinvasive management of acute ST-segment elevation myocardial infarction: Insights from the TRANSFER-AMI trial. American Heart Journal 163:2, 176-181.e2
CrossRef10
Ludovic Drouet. (2012) Low molecular weight heparin biosimilars: how much similarity for how much clinical benefit?. Targeted Oncology
CrossRef11
Marc Cohen, Walter P. Jeske, Jose C. Nicolau, Gilles Montalescot, Jawed Fareed. (2012) US Food and Drug Administration approval of generic versions of complex biologics: implications for the practicing physician using low molecular weight heparins. Journal of Thrombosis and Thrombolysis
CrossRef12
Elliott M. Antman. 2012. ST-Segment Elevation Myocardial Infarction. , 1087-1110.
CrossRef13
Elliott M. Antman, David A. Morrow. 2012. ST-Segment Elevation Myocardial Infarction. , 1111-1177.
CrossRef14
Matthews Chacko, Rani Hasan. 2012. Thrombolytic Intervention. , 142-158.
CrossRef15
Jeffrey L. Anderson. 2012. ST Segment Elevation Acute Myocardial Infarction and Complications of Myocardial Infarction. , 434-448.
CrossRef16
David F. M. Brown. 2011. ST-Segment Elevation Myocardial Infarction. , 38-53.
CrossRef17
Leong Lee, Derek Chew. (2011) Promise of Factor Xa Inhibition in Acute Coronary Syndromes. Current Cardiology Reports
CrossRef18
Álvaro Merino, Inmaculada Roldán, Francisco Marín, Fernando Worner. (2011) Prevención de complicaciones hemorrágicas en el síndrome coronario agudo. Medicina Clínica 137:14, 650-655
CrossRef19
Etienne Puymirat, Nadia Aïssaoui, Jean-Philippe Collet, Aurès Chaib, Jean-Louis Bonnet, Vincent Bataille, Elodie Drouet, Geneviève Mulak, Jean Ferrières, Didier Blanchard, Tabassome Simon, Nicolas Danchin. (2011) Comparison of bleeding complications and one-year survival of low molecular weight heparin versus unfractioned heparin for acute myocardial infarction in elderly patients. The FAST-MI registry. International Journal of Cardiology
CrossRef20
Jean-Pierre Bassand. (2011) Current antithrombotic agents for acute coronary syndromes: Focus on bleeding risk. International Journal of Cardiology
CrossRef21
David H. Fitchett, Pierre Theroux, James M. Brophy, Warren J. Cantor, Jafna L. Cox, Milan Gupta, Heather Kertland, Shamir R. Mehta, Robert C. Welsh, Shaun G. Goodman. (2011) Assessment and Management of Acute Coronary Syndromes (ACS): A Canadian Perspective on Current Guideline-Recommended Treatment – Part 2: ST-Segment Elevation Myocardial Infarction. Canadian Journal of Cardiology 27:6, S402-S412
CrossRef22
Marco Tubaro, Nicolas Danchin, Patrick Goldstein, Gerasimos Filippatos, Yonathan Hasin, Magda Heras, Petr Jansky, Tone M. Norekval, Eva Swahn, Kristian Thygesen, Christiaan Vrints, Doron Zahger, Hans R. Arntz, Abdelouahab Bellou, Jean E. De La Coussaye, Leonardo De Luca, Kurt Huber, Yves Lambert, Maddalena Lettino, Bertil Lindahl, Scott Mclean, Lutz Nibbe, William F. Peacock, Susanna Price, Tom Quinn, Christian Spaulding, Gabriel Tatu-Chitoiu, Frans Van De Werf. (2011) Tratamiento prehospitalario de los pacientes con IAMCEST. Una declaración científica del Working Group Acute Cardiac Care de la European Society of Cardiology. Revista Española de Cardiología
CrossRef23
N. Assez, E. Wiel, C. Lemanski-Brulin, C. Adriansen, P. Goldstein. (2011) Syndromes coronariens aigus : prise en charge thérapeutique en urgence. Annales françaises de médecine d'urgence
CrossRef24
Allison Burnett, Jason Cohen, David A. Garcia. 2011. Hemorrhagic Complications of Anticoagulants in Hospitalized Patients. , 291-330.
CrossRef25
Gilles Montalescot, Uwe Zeymer, Johanne Silvain, Bertrand Boulanger, Marc Cohen, Patrick Goldstein, Patrick Ecollan, Xavier Combes, Kurt Huber, Charles Pollack, Jean-François Bénezet, Olivier Stibbe, Emmanuelle Filippi, Emmanuel Teiger, Guillaume Cayla, Simon Elhadad, Frédéric Adnet, Tahar Chouihed, Sébastien Gallula, Agnès Greffet, Mounir Aout, Jean-Philippe Collet, Eric Vicaut. (2011) Intravenous enoxaparin or unfractionated heparin in primary percutaneous coronary intervention for ST-elevation myocardial infarction: the international randomised open-label ATOLL trial. The Lancet 378:9792, 693-703
CrossRef26
Gregg W Stone, E Magnus Ohman. (2011) Antithrombin alternatives in STEMI. The Lancet 378:9792, 643-645
CrossRef27
Charles F. Jackson, Nanette K. Wenger. (2011) Cardiovascular Disease in the Elderly. Revista Española de Cardiología (English Edition) 64:8, 697-712
CrossRef28
Charles F. Jackson, Nanette K. Wenger. (2011) Enfermedad cardiovascular en el anciano. Revista Española de Cardiología 64:8, 697-712
CrossRef29
E. P. Navarese, G. De Luca, F. Castriota, M. Kozinski, P. Gurbel, C. M. Gibson, F. Andreotti, A. Buffon, J. M. Siller-Matula, A. Sukiennik, S. De Servi, J. Kubica. (2011) Low-Molecular-Weight Heparins vs Unfractionated Heparin in the Setting of Percutaneous Coronary Intervention for ST-elevation Myocardial Infarction: a Meta-analysis. Journal of Thrombosis and Haemostasisno-no
CrossRef30
M. Tubaro, N. Danchin, P. Goldstein, G. Filippatos, Y. Hasin, M. Heras, P. Jansky, T. M. Norekval, E. Swahn, K. Thygesen, C. Vrints, D. Zahger, H. R. Arntz, A. Bellou, J. E. de La Coussaye, L. de Luca, K. Huber, Y. Lambert, M. Lettino, B. Lindahl, S. McLean, L. Nibbe, W. F. Peacock, S. Price, T. Quinn, C. Spaulding, G. Tatu-Chitoiu, F. van de Werf. (2011) Pre-hospital treatment of STEMI patients. A scientific statement of the Working Group Acute Cardiac Care of the European Society of Cardiology. Acute Cardiac Care 13:2, 56-67
CrossRef31
Zafar Iqbal, Marc Cohen. (2011) Enoxaparin: a pharmacologic and clinical review. Expert Opinion on Pharmacotherapy 12:7, 1157-1170
CrossRef32
L. Drouet. (2011) Biosimilaires d’héparine de bas poids moléculaire: quel degré de similarité pour quel bénéfice clinique ?. Oncologie 13:5, 239-246
CrossRef33
R. Scott Wright, Jeffrey L. Anderson, Cynthia D. Adams, Charles R. Bridges, Donald E. Casey, Steven M. Ettinger, Francis M. Fesmire, Theodore G. Ganiats, Hani Jneid, A. Michael Lincoff, Eric D. Peterson, George J. Philippides, Pierre Theroux, Nanette K. Wenger, James Patrick Zidar. (2011) 2011 ACCF/AHA Focused Update Incorporated Into the ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non–ST-Elevation Myocardial Infarction. Journal of the American College of Cardiology 57:19, e215-e367
CrossRef34
Eric Heller, George D. Dangas. 2011. Heparin, LMWH, GIIb/IIIa, and Direct Thrombin Inhibitors. , 110-143.
CrossRef35
Rahul Sakhuja, Robert W. Yeh, Deepak L. Bhatt. (2011) Anticoagulant Agents in Acute Coronary Syndromes. Current Problems in Cardiology 36:4, 127-168
CrossRef36
Amelia Carro, Rachel Bastiaenen, Juan Carlos Kaski. (2011) Age Related Issues in Reperfusion of Myocardial Infarction. Cardiovascular Drugs and Therapy 25:2, 139-148
CrossRef37
David Brieger, Jean-Philippe Collet, Johanne Silvain, Antoine Landivier, Olivier Barthélémy, Farzin Beygui, Anne Bellemain-Appaix, Anne Mercadier, Remi Choussat, Nicolas Vignolles, Dominique Costagliola, Gilles Montalescot. (2011) Heparin or enoxaparin anticoagulation for primary percutaneous coronary intervention. Catheterization and Cardiovascular Interventions 77:2, 182-190
CrossRef38
Vicente Peral, Andrés Carrillo, Armando Bethencourt, Miguel Fiol, Alfredo Gómez-Jaume, Mar Alameda, Marcos Pascual, Carlos Fernández-Palomeque, Catalina Rubert, Lorenzo Socías. (2011) Modelo de intervención coronaria percutánea primaria en las Islas Baleares. Revista Española de Cardiología Suplementos 11, 35-43
CrossRef39
Shannon M. Bates, Jeffrey I. Weitz. 2011. Anticoagulants. , 232-252.
CrossRef40
Joanne Mazzarelli, Steven M. Hollenberg. 2011. Acute Coronary Syndromes. , 548-558.
CrossRef41
T. Petrovic, K. Tazarourte, C. Lapandry, F. Adnet, F. Lapostolle. (2010) Syndrome coronaire aigu avec élévation du segment ST : stratégies de prise en charge en préhospitalier. Annales de Cardiologie et d'Angéiologie 59:6, 329-334
CrossRef42
V. Wenzel, S.G. Russo, H.R. Arntz, J. Bahr, M.A. Baubin, B.W. Böttiger, B. Dirks, U. Kreimeier, M. Fries, C. Eich. (2010) Kommentar zu den Leitlinien 2010 zur kardiopulmonalen Reanimation des European Resuscitation Council. Der Anaesthesist 59:12, 1105-1123
CrossRef43
H. Benamer, B. Meftout, B. Chevalier. (2010) Le risque de saignement dans les syndromes coronariens aigus avec sus-décalage du segment ST. Annales de Cardiologie et d'Angéiologie 59:6, 356-361
CrossRef44
P. Aubry, X. Halna du Fretay. (2010) Traitements antithrombotiques du syndrome coronarien aigu avec sus-décalage ST. Annales de Cardiologie et d'Angéiologie 59:6, 335-343
CrossRef45
Mitul B. Kadakia, Nihar R. Desai, Karen P. Alexander, Anita Y. Chen, JoAnne M. Foody, Christopher P. Cannon, Stephen D. Wiviott, Benjamin M. Scirica. (2010) Use of Anticoagulant Agents and Risk of Bleeding Among Patients Admitted With Myocardial Infarction. JACC: Cardiovascular Interventions 3:11, 1166-1177
CrossRef46
H.-R. Arntz, L.L. Bossaert, N. Danchin, N. Nicolau. (2010) Initiales Management des akuten Koronarsyndroms. Notfall + Rettungsmedizin 13:7, 621-634
CrossRef47
Zafar Iqbal, Marc Cohen. (2010) Emerging antithrombotic agents: what does the intensivist need to know?. Current Opinion in Critical Care 16:5, 419-425
CrossRef48
Leo Bossaert, Robert E. O’Connor, Hans-Richard Arntz, Steven C. Brooks, Deborah Diercks, Gilson Feitosa-Filho, Jerry P. Nolan, Terry L. Vanden Hoek, Darren L. Walters, Aaron Wong, Michelle Welsford, Karen Woolfrey. (2010) Part 9: Acute coronary syndromes. Resuscitation 81:1, e175-e212
CrossRef49
Hans-Richard Arntz, Leo L. Bossaert, Nicolas Danchin, Nikolaos I. Nikolaou. (2010) European Resuscitation Council Guidelines for Resuscitation 2010 Section 5. Initial management of acute coronary syndromes. Resuscitation 81:10, 1353-1363
CrossRef50
Malak El-Rayes, Erick Schampaert, Jean-Claude Tardif, Mark J. Eisenberg, Marc Afilalo, Simon Kouz, Claude Lauzon, Richard Harvey, Michel Nguyen, Remi Kouz, Jean-Pierre Dery, Samer Mansour, Anne-Marie Van Kieu, Stephane Rinfret, Thao Huynh. (2010) Safety and effectiveness of enoxaparin following fibrinolytic therapy: Results of the Acute Myocardial Infarction (AMI)-QUEBEC registry. Canadian Journal of Cardiology 26:8, 431-436
CrossRef51
Jonathan D. Rich, Christopher P. Cannon, Sabina A. Murphy, Jie Qin, Robert P. Giugliano, Eugene Braunwald. (2010) Prior Aspirin Use and Outcomes in Acute Coronary Syndromes. Journal of the American College of Cardiology 56:17, 1376-1385
CrossRef52
Brian L. Henry, Umesh R. Desai. 2010. Anticoagulants. .
CrossRef53
D. A. Morrow, E. M. Antman, K. A. A. Fox, H. D. White, R. Giugliano, S. A. Murphy, C. H. McCabe, E. Braunwald, . (2010) One-year outcomes after a strategy using enoxaparin vs. unfractionated heparin in patients undergoing fibrinolysis for ST-segment elevation myocardial infarction: 1-year results of the ExTRACT-TIMI 25 Trial. European Heart Journal 31:17, 2097-2102
CrossRef54
P. Sinnaeve, F. Van de Werf. (2010) Enoxaparin and fibrinolysis: ExTRACTing prognosis from bleeding complications. European Heart Journal 31:17, 2077-2079
CrossRef55
R. P. Giugliano, R. R. Giraldez, D. A. Morrow, E. M. Antman, C. M. Gibson, S. Mohanavelu, S. A. Murphy, C. H. McCabe, E. Braunwald. (2010) Relations between bleeding and outcomes in patients with ST-elevation myocardial infarction in the ExTRACT-TIMI 25 trial. European Heart Journal 31:17, 2103-2110
CrossRef56
Michael C Reed, Brahmajee K Nallamothu. (2010) Optimizing primary percutaneous coronary intervention in ST-segment elevation myocardial infarction. Interventional Cardiology 2:4, 449-453
CrossRef57
Osmund Bertel, David Ramsay, Tobias Wettstein, David Kurz, Irene Stettler, Edwin Straumann, Juergen Frielingsdorf, Dominik Maurer, Barbara Naegeli. (2010) Intravenous enoxaparin versus unfractionated heparin in unselected patients undergoing percutaneous coronary interventions: the Zurich enoxaparin versus unfractionated heparin in PCI study (ZEUS). EuroIntervention 6:3, 407-412
CrossRef58
Alex Hobson, Nick Curzen. 2010. Acute Coronary Syndromes and Myocardial Infarction. , 234-255.
CrossRef59
Edmundas Kadusevicius, Gabriele Kildonaviciute, Birute Varanaviciene, Danguole Jankauskiene. (2010) Low-molecular-weight heparins: Pharmacoeconomic decision modeling based on meta-analysis data. International Journal of Technology Assessment in Health Care 26:03, 272-279
CrossRef60
Paul W. Armstrong, Anthony Gershlick, Patrick Goldstein, Robert Wilcox, Thierry Danays, Erich Bluhmki, Frans Van de Werf. (2010) The Strategic Reperfusion Early After Myocardial Infarction (STREAM) study. American Heart Journal 160:1, 30-35.e1
CrossRef61
J. Hankowitz, P. Bramlage. (2010) Pharmaka zur Thrombozyten- und Gerinnungshemmung in der Behandlung des akuten Koronarsyndroms. Der Kardiologe 4:3, 239-248
CrossRef62
R. John Simes, Rachel L. O'Connell, Philip E. Aylward, Sergei Varshavsky, Rafael Diaz, Robert G. Wilcox, Paul W. Armstrong, Christopher B. Granger, John K. French, Frans Van de Werf, Ian C. Marschner, Rob Califf, Harvey D. White. (2010) Unexplained international differences in clinical outcomes after acute myocardial infarction and fibrinolytic therapy: Lessons from the Hirulog and Early Reperfusion or Occlusion (HERO)-2 trial. American Heart Journal 159:6, 988-997
CrossRef63
John C. Marshall, R. Phillip Dellinger, Mitchell Levy. (2010) The Surviving Sepsis Campaign: A History and a Perspective. Surgical Infections 11:3, 275-281
CrossRef64
S. Michael Gharacholou, Renato D. Lopes, Jeffrey B. Washam, L. Kristin Newby, Stefan K. James, John H. Alexander. (2010) Antithrombotic therapy in acute coronary syndromes: guidelines translated for the clinician. Journal of Thrombosis and Thrombolysis 29:4, 516-528
CrossRef65
José Martínez-González, Cristina Rodríguez. (2010) New challenges for a second-generation low-molecular-weight heparin: focus on bemiparin. Expert Review of Cardiovascular Therapy 8:5, 625-634
CrossRef66
Marc Cohen, Catalin Boiangiu, Mateen Abidi. (2010) Therapy for ST-Segment Elevation Myocardial Infarction Patients Who Present Late or Are Ineligible for Reperfusion Therapy. Journal of the American College of Cardiology 55:18, 1895-1906
CrossRef67
Yong-Jian Li, Seung-Woon Rha, Kang-Yin Chen, Kanhaiya L. Poddar, Zhe Jin, Yoshiyasu Minami, Lin Wang, Qun Dang, Guang-Ping Li, Sureshkumar Ramasamy, Ji-Young Park, Chol Ung Choi, Jin-Won Kim, Eung Ju Kim, Chang Gyu Park, Hong Seog Seo, Dong Joo Oh, Myung Ho Jeong, Young Keun Ahn, Taek Jong Hong, Jong-Seon Park, Young Jo Kim, Seung Ho Hur, In Whan Seong, Jei Keon Chae, Myeong Chan Cho, Jang Ho Bae, Dong Hoon Choi, Yang Soo Jang, In Ho Chae, Hyo Soo Kim, Chong Jin Kim, Jung Han Yoon, Tae Hoon Ahn, Seung-Jea Tahk, Wook Sung Chung, Ki Bae Seung, Seung Jung Park. (2010) Low-molecular-weight heparin versus unfractionated heparin in acute ST-segment elevation myocardial infarction patients undergoing primary percutaneous coronary intervention with drug-eluting stents. American Heart Journal 159:4, 684-690.e1
CrossRef68
José G. Díez, James M. Wilson. (2010) Practical Strategies for the Management of Anticoagulation Therapy: Unsolved Issues in the Cardiac Catheterization Laboratory. Cardiovascular Drugs and Therapy 24:2, 161-174
CrossRef69
Ian Menown, Gilles Montalescot, Nikhal Pal, Carrie Fidler, Michelle Orme, Samantha Gillard. (2010) Enoxaparin is a cost-effective adjunct to fibrinolytic therapy for ST-elevation myocardial infarction in contemporary practice. Advances in Therapy 27:3, 181-191
CrossRef70
Elias B. Hanna, David Luke Glancy, Jorge F. Saucedo. (2010) Antiplatelet and Anticoagulant Therapies in Acute Coronary Syndromes. Cardiovascular Drugs and Therapy 24:1, 61-70
CrossRef71
Gilles Montalescot, Stephen G. Ellis, Mark A. de Belder, Luc Janssens, Olivier Katz, Wladyslaw Pluta, Patrick Ecollan, Michal Tendera, Ad J. van Boven, Petr Widimsky, Henning R. Andersen, Amadeo Betriu, Paul Armstrong, Bruce R. Brodie, Howard C. Herrmann, Franz-Josef Neumann, Mark B. Effron, Jiandong Lu, Elliot S. Barnathan, Eric J. Topol. (2010) Enoxaparin in Primary and Facilitated Percutaneous Coronary Intervention. JACC: Cardiovascular Interventions 3:2, 203-212
CrossRef72
Marc Cohen. (2010) The Thrombin Hypothesis in ACS: A Disappointing Disconnect between Bench Data and Bedside Clinical Trials. The American Journal of Medicine 123:2, 103-110
CrossRef73
Jung Sun Cho, Sung-Ho Her, Ju Yeal Baek, Mahn-Won Park, Hyoung Doo Kim, Myung Ho Jeong, Young keun Ahn, Shung Chull Chae, Seung Ho Hur, Taek Jong Hong, Young Jo Kim, In Whan Seong, Jei Keon Chae, Jay Young Rhew, In Ho Chae, Myeong Chan Cho, Jang Ho Bae, Seung Woon Rha, Chong Jim Kim, Donghoon Choi, Yang Soo Jang, Junghan Yoon, Wook Sung Chung, Jeong Gwan Cho, Ki Bae Seung, Seung Jung Park, . (2010) Clinical Benefit of Low Molecular Weight Heparin for ST-segment Elevation Myocardial Infarction Patients Undergoing Primary Percutaneous Coronary Intervention with Glycoprotein IIb/IIIa Inhibitor. Journal of Korean Medical Science 25:11, 1601
CrossRef74
Serdar Farhan, Thomas Höchtl, Alexandra Kautzky-Willer, Johann Wojta, Kurt Huber. (2010) Antithrombotic therapy in patients with coronary artery disease and with type 2 diabetes mellitus. Wiener Medizinische Wochenschrift 160:1-2, 30-38
CrossRef75
James R. Harkness, Marc S. Sabatine, Eugene Braunwald, David A. Morrow, Sarah Sloan, Stephen D. Wiviott, Robert P. Giugliano, Elliott M. Antman, Christopher P. Cannon, Benjamin M. Scirica. (2010) Extent of ST-segment resolution after fibrinolysis adds improved risk stratification to clinical risk score for ST-segment elevation myocardial infarction. American Heart Journal 159:1, 55-62
CrossRef76
Robert C. Welsh, Luc Sauriol, Zugui Zhang, Paul Kolm, William S. Weintraub, Pierre Theroux. (2009) Cost-effectiveness of enoxaparin compared with unfractionated heparin in ST elevation myocardial infarction patients undergoing pharmacological reperfusion: A Canadian analysis of the Enoxaparin and Thrombolysis Reperfusion for Acute Myocardial Infarction Treatment – Thrombolysis in Myocardial Infarction (ExTRACT-TIMI) 25 trial. Canadian Journal of Cardiology 25:12, e399-e405
CrossRef77
Michael A. Barras, Stephen B. Duffull, John J. Atherton, Bruce Green. (2009) Modelling the occurrence and severity of enoxaparin-induced bleeding and bruising events. British Journal of Clinical Pharmacology 68:5, 700-711
CrossRef78
Deepak Thomas, Robert P. Giugliano. (2009) Management of ST-segment elevation myocardial infarction: Comparison of the updated guidelines from North America and Europe. American Heart Journal 158:5, 695-705
CrossRef79
Amit Kumar, Christopher P. Cannon. (2009) Acute Coronary Syndromes: Diagnosis and Management, Part II. Mayo Clinic Proceedings 84:11, 1021-1036
CrossRef80
Frederick Leri, Stephen J. Voyce, Salvatore Scialla, William Glavich, Edward Dzielak, Raymond A. Smego, John Guzek. (2009) Enoxaparin dosing in the elderly using adjusted body weight. Journal of Thrombosis and Thrombolysis 28:3, 348-353
CrossRef81
Patrick Goldstein, Frederic Lapostolle, Gabriel Steg, Nicolas Danchin, Nathalie Assez, Gilles Montalescot, Sandrine Charpentier, Eric Wiel, Jean Michel Juliard. (2009) Lowering mortality in ST-elevation myocardial infarction and non-ST-elevation myocardial infarction: key prehospital and emergency room treatment strategies. European Journal of Emergency Medicine 16:5, 244-255
CrossRef82
Leslee J. Shaw, Raffaelle Bugiardini, C. Noel Bairey Merz. (2009) Women and Ischemic Heart Disease. Journal of the American College of Cardiology 54:17, 1561-1575
CrossRef83
Marc P. Bonaca, Philippe Gabriel Steg, Laurent J. Feldman, John F. Canales, James J. Ferguson, Lars Wallentin, Robert M. Califf, Robert A. Harrington, Robert P. Giugliano. (2009) Antithrombotics in Acute Coronary Syndromes. Journal of the American College of Cardiology 54:11, 969-984
CrossRef84
Rohit Seth Loomba, Rohit Arora. (2009) ST Elevation Myocardial Infarction Guidelines Today: A Systematic Review Exploring Updated ACC/AHA STEMI Guidelines and Their Applications. American Journal of Therapeutics 16:5, e7-e13
CrossRef85
Leo Marcoff, Zugui Zhang, Wei Zhang, Edward Ewen, Claudine Jurkovitz, Prisca Leguet, Paul Kolm, William S. Weintraub. (2009) Cost Effectiveness of Enoxaparin in Acute ST-Segment Elevation Myocardial Infarction. Journal of the American College of Cardiology 54:14, 1271-1279
CrossRef86
Jack L. Martin, Edward T. A. Fry, Todd Martin, Trevor H. Atherley, Seth S. Martin, Marvin J. Slepian. (2009) The pharmacodynamics of enoxaparin in percutaneous coronary intervention with precise rapid enoxaparin loading (PEPCI-PRE study). Journal of Thrombosis and Thrombolysis 28:2, 224-228
CrossRef87
Ludovic Drouet, Claire Bal dit Sollier, Jack Martin. (2009) Adding intravenous unfractionated heparin to standard enoxaparin causes excessive anticoagulation not detected by activated clotting time: Results of the STACK-on to ENOXaparin (STACKENOX) study. American Heart Journal 158:2, 177-184
CrossRef88
Roberto R. Giraldez, Stephen D. Wiviott, Jose C. Nicolau, Satishkumar Mohanavelu, David A. Morrow, Elliott M. Antman, Robert P. Giugliano. (2009) Streptokinase and Enoxaparin as an Alternative to Fibrin-Specific Lytic-Based Regimens. Drugs 69:11, 1433-1443
CrossRef89
Dmitriy Kireyev, Edward C. Yun, Brian J. Page, William E. Boden. (2009) Medical therapy in acute coronary syndromes: Which medicines and at what doses?. Current Cardiology Reports 11:4, 267-275
CrossRef90
Sarabjeet Singh, Amol Bahekar, Janos Molnar, Sandeep Khosla, Rohit Arora. (2009) Adjunctive Low Molecular Weight Heparin During Fibrinolytic Therapy in Acute ST-Segment Elevation Myocardial Infarction: A Meta-Analysis Of Randomized Control Trials. Clinical Cardiology 32:7, 358-364
CrossRef91
Jose C Nicolau, Marc Cohen, Gilles Montalescot. (2009) Differences Among Low-Molecular-Weight Heparins: Evidence in Patients With Acute Coronary Syndromes. Journal of Cardiovascular Pharmacology 53:6, 440-445
CrossRef92
Judd E. Hollander, C. Michael Gibson, Charles V. Pollack. (2009) Hospitals with and without percutaneous coronary intervention capability: considerations for treating acute coronary syndromes. The American Journal of Emergency Medicine 27:5, 595-606
CrossRef93
N. Danchin, R. Carda, A. Chaib, A. Lepillier, E. Durand. (2009) Optimizing outcomes in patients with STEMI: mortality, bleeding, door-to-balloon times, and guidelines: the approach to regional systems for STEMI care: defining the ideal approach to reperfusion therapy based on recent trials. European Heart Journal Supplements 11:Suppl C, C25-C30
CrossRef94
Simon J. McRae, John W. Eikelboom. 2009. Anticoagulation in Acute Coronary Syndromes. , 171-196.
CrossRef95
Cheuk-Kit Wong, Harvey D. White. 2009. Fibrinolysis for Acute Myocardial Infarction. , 651-666.
CrossRef96
H. Thiele. (2009) Optimales prähospitales Management des ST-Strecken-Hebungsinfarktes. Clinical Research in Cardiology Supplements 4:S2, 142-149
CrossRef97
Rajiv Gulati, Bernard J. Gersh. (2009) Tratamiento antitrombótico para la prevención del reinfarto tras la reperfusión: el precio del éxito. Revista Española de Cardiología 62:5, 474-478
CrossRef98
Nicolas Meneveau, Marie France Séronde, Vincent Descotes-Genon, Joanna Dutheil, Romain Chopard, Fiona Ecarnot, Florent Briand, Yvette Bernard, François Schiele, Jean-Pierre Bassand. (2009) Immediate versus delayed angioplasty in infarct-related arteries with TIMI III flow and ST segment recovery: a matched comparison in acute myocardial infarction patients. Clinical Research in Cardiology 98:4, 257-264
CrossRef99
Roberto R. Giraldez, Marc S. Sabatine, David A. Morrow, Satishkumar Mohanavelu, Carolyn H. McCabe, Elliott M. Antman, Eugene Braunwald. (2009) Baseline hemoglobin concentration and creatinine clearance composite laboratory index improves risk stratification in ST-elevation myocardial infarction. American Heart Journal 157:3, 517-524
CrossRef100
Paul J.P.C. van den Bergh, Peter C. Kievit, Marc A. Brouwer, Wim R.M. Aengevaeren, Gerrit Veen, Freek W.A. Verheugt. (2009) Prolonged anticoagulation therapy adjunctive to aspirin after successful fibrinolysis: From early reduction in reocclusion to improved long-term clinical outcome. American Heart Journal 157:3, 532-540
CrossRef101
Giovanni Melandri, Franco Semprini, Samuele Nanni, Daniela Calabrese, Fabio Vagnarelli, Angelo Branzi. (2009) Why and when PCI, why and when thrombolysis?. Internal and Emergency Medicine 4:1, 3-5
CrossRef102
Arne Kristian Schwarz, Uwe Zeymer. (2009) Enoxaparin in patients with primary percutaneous coronary intervention for acute ST segment elevation myocardial infarction. Future Cardiology 5:1, 43-49
CrossRef103
Tomislav Kostic, Zoran Perisic, Dragan Milic, Svetlana Apostolovic, Sonja Salinger-Martinovic, Nenad Bozinovic, Vladimir Mitov, Miroslav Vidanovic. (2009) Coronary flow and hemorrhagic complications after alteplase and streptokinase administration in patients with acute myocardial infarction. Vojnosanitetski pregled 66:3, 218-222
CrossRef104
Robert C. Welsh, Andrew Travers, Thao Huynh, Warren J. Cantor. (2009) Canadian Cardiovascular Society Working Group: Providing a perspective on the 2007 focused update of the American College of Cardiology and American Heart Association 2004 guidelines for the management of ST elevation myocardial infarction. Canadian Journal of Cardiology 25:1, 25-32
CrossRef105
Grace H. Kim, David K. Hahn, Christopher P. Kellner, Ricardo J. Komotar, Robert Starke, Matthew C. Garrett, Jiang Yao, Justin Cleveland, Stephan A. Mayer, E. Sander Connolly. (2009) The incidence of heparin-induced thrombocytopenia Type II in patients with subarachnoid hemorrhage treated with heparin versus enoxaparin. Journal of Neurosurgery 110:1, 50-57
CrossRef106
F. J. VAN DE WERF, E. J. TOPOL, B. E. SOBEL. (2009) The impact of fibrinolytic therapy for ST-segment-elevation acute myocardial infarction. Journal of Thrombosis and Haemostasis 7:1, 14-20
CrossRef107
Deepak Thomas, Robert P. Giugliano. (2009) ExTRACT-TIMI 25 in perspective: key lessons regarding enoxaparin as an adjunct to fibrinolytic therapy. Journal of Thrombosis and Thrombolysis 27:1, 1-10
CrossRef108
Uwe Zeymer, Anselm Gitt, Ralf Zahn, Claus Jünger, Timm Bauer, Tobias Heer, Oliver Koeth, Jochen Senges. (2009) Efficacy and safety of enoxaparin in combination with and without GP IIb/IIIa inhibitors in unselected patients with ST segment elevation myocardial infarction treated with primary percutaneous coronary intervention. EuroIntervention 4:4, 524-528
CrossRef109
C. Michael Gibson, Yuri B. Pride, Philip E. Aylward, Jacques J. Col, Shaun G. Goodman, Dietrich Gulba, Mijo Bergovec, Vijayalakshmi Kunadian, Cafer Zorkun, Jacqueline L. Buros, Sabina A. Murphy, Elliott M. Antman. (2009) Association of non-steroidal anti-inflammatory drugs with outcomes in patients with ST-segment elevation myocardial infarction treated with fibrinolytic therapy: an ExTRACT-TIMI 25 analysis. Journal of Thrombosis and Thrombolysis 27:1, 11-17
CrossRef110
Avi Levin, Moshe Ben-Artzi, Pazit Beckerman, Guy Haber, David Varon, Arie Ben-Yehuda, Mordechai Muszkat. (2009) Factors Associated with Bleeding in Elderly Hospitalized Patients Treated with Enoxaparin Sodium. Drugs & Aging 26:1, 77-85
CrossRef111
Christopher P. Cannon. (2008) Updated Strategies and Therapies for Reducing Ischemic and Vascular Events (STRIVE) ST-Segment Elevation Myocardial Infarction Critical Pathway Toolkit. Critical Pathways in Cardiology: A Journal of Evidence-Based Medicine 7:4, 223-231
CrossRef112
Cheuk-Kit Wong, Harvey D White. (2008) Enoxaparin: a perspective on its use for coronary artery disease. Aging Health 4:6, 579-591
CrossRef113
C. Michael Gibson, Yuri B. Pride, Paul D. Frederick, Charles V. Pollack, John G. Canto, Alan J. Tiefenbrunn, W. Douglas Weaver, Costas T. Lambrew, William J. French, Eric D. Peterson, William J. Rogers. (2008) Trends in reperfusion strategies, door-to-needle and door-to-balloon times, and in-hospital mortality among patients with ST-segment elevation myocardial infarction enrolled in the National Registry of Myocardial Infarction from 1990 to 2006. American Heart Journal 156:6, 1035-1044
CrossRef114
Marc Cohen. (2008) High-risk Acute Coronary Syndrome Patients with Non-ST-Elevation Myocardial Infarction: Definition and Treatment. Cardiovascular Drugs and Therapy 22:5, 407-418
CrossRef115
Marc Cohen, James Hoekstra. (2008) The use of adjunctive anticoagulants in patients with acute coronary syndrome transitioning to percutaneous coronary intervention. The American Journal of Emergency Medicine 26:8, 932-941
CrossRef116
Sargis Khoobiar, Nicolai Mejevoi, Khalil Kaid, Catalin Boiangiu, Sampoornima Setty, Anjum Tanwir, Khaula Khalid, Marc Cohen. (2008) Primary percutaneous coronary intervention for ST-elevation myocardial infarction using an intravenous and subcutaneous enoxaparin low molecular weight heparin regimen. Journal of Thrombosis and Thrombolysis 26:2, 85-90
CrossRef117
Charles V. Pollack, Elliott M. Antman, Judd E. Hollander. (2008) 2007 Focused Update to the ACC/AHA Guidelines for the Management of Patients With ST-Segment Elevation Myocardial Infarction: Implications for Emergency Department Practice. Annals of Emergency Medicine 52:4, 344-355.e1
CrossRef118
Tracy Y. Wang, Anita Y. Chen, Karen P. Alexander, E. Magnus Ohman, W. Brian Gibler, Eric D. Peterson, Matthew T. Roe. (2008) Excess Heparin Dosing Among Fibrinolytic-treated Patients with ST-Segment Elevation Myocardial Infarction. The American Journal of Medicine 121:9, 805-810
CrossRef119
H.R. Arntz. (2008) Therapie des akuten Myokardinfarkts in der Prähospitalphase. Der Internist 49:9, 1023-1030
CrossRef120
Harvey D White, Derek P Chew. (2008) Acute myocardial infarction. The Lancet 372:9638, 570-584
CrossRef121
David Fitchett. (2008) Tailored antithrombotic therapy for acute coronary syndromes. Expert Review of Cardiovascular Therapy 6:7, 935-944
CrossRef122
Freek WA Verheugt. (2008) Long-term anticoagulation in patients with coronary disease, and future developments. Current Opinion in Cardiology 23:4, 315-319
CrossRef123
David P. Faxon. (2008) New data on early management of patients with ST-elevation myocardial infarction. Current Cardiology Reports 10:4, 291-298
CrossRef124
Peter E. Ruchin, Marino Labinaz. (2008) Which heparin and how much?. Current Cardiology Reports 10:4, 312-318
CrossRef125
José Martínez-González, Luis Vila, Cristina Rodríguez. (2008) Bemiparin: second-generation, low-molecular-weight heparin for treatment and prophylaxis of venous thromboembolism. Expert Review of Cardiovascular Therapy 6:6, 793-802
CrossRef126
MA Barras, SB Duffull, JJ Atherton, B Green. (2008) Individualized Compared With Conventional Dosing of Enoxaparin. Clinical Pharmacology & Therapeutics 83:6, 882-888
CrossRef127
H.-R. Arntz. (2008) Reperfusion strategies in ST-elevation myocardial infarction—Current status and perspectives for early and pre-hospital treatment. Resuscitation 77:3, 296-305
CrossRef128
Marc A. Brouwer, Peter C. Kievit, Hendrik-Jan Dieker, Gerrit Veen, Aart J. Karreman, Freek W.A. Verheugt. (2008) Sustained coronary patency after fibrinolytic therapy as independent predictor of 10-year cardiac survival. American Heart Journal 155:6, 1039-1046
CrossRef129
Charles V. Pollack, A. David Goldberg. (2008) The Medical Management of Acute Coronary Syndromes and Potential Roles for New Antithrombotic Agents. The Journal of Emergency Medicine 34:4, 417-428
CrossRef130
Peter R. Sinnaeve, Frans J. Van de Werf. 2008. Bolus Fibrinolytic Therapy. , 59-70.
CrossRef131
Robert C Welsh, Paul W Armstrong. 2008. Treatment Opportunities with Fibrinolytic Therapy. , 71-90.
CrossRef132
E. Marc Jolicoeur, Christopher B. Granger. 2008. Anticoagulant Agents. , 195-232.
CrossRef133
Carlo Di Mario, Dariusz Dudek, Federico Piscione, Waldemar Mielecki, Stefano Savonitto, Ernesto Murena, Konstantinos Dimopoulos, Antonio Manari, Achille Gaspardone, Andrzej Ochala, Krzysztof Zmudka, Leonardo Bolognese, Philippe Gabriel Steg, Marcus Flather. (2008) Immediate angioplasty versus standard therapy with rescue angioplasty after thrombolysis in the Combined Abciximab REteplase Stent Study in Acute Myocardial Infarction (CARESS-in-AMI): an open, prospective, randomised, multicentre trial. The Lancet 371:9612, 559-568
CrossRef134
Hitinder S. Gurm, Kim A. Eagle. (2008) Use of Anticoagulants in ST-Segment Elevation Myocardial Infarction Patients; A Focus on Low-Molecular-Weight Heparin. Cardiovascular Drugs and Therapy 22:1, 59-69
CrossRef135
John F Canales, James J Ferguson. (2008) Low-Molecular-Weight Heparins. American Journal of Cardiovascular Drugs 8:1, 15-25
CrossRef136
Giuseppe De Luca, Paolo Marino. (2008) Antithrombotic Therapies in Primary Angioplasty. Drugs 68:16, 2325-2344
CrossRef137
Deborah B. Diercks, Michael C. Kontos, Jim E. Weber, Ezra A. Amsterdam. (2008) Management of ST-segment elevation myocardial infarction in EDs. The American Journal of Emergency Medicine 26:1, 91-100
CrossRef138
Elliott M. Antman, Mary Hand, Paul W. Armstrong, Eric R. Bates, Lee A. Green, Lakshmi K. Halasyamani, Judith S. Hochman, Harlan M. Krumholz, Gervasio A. Lamas, Charles J. Mullany, David L. Pearle, Michael A. Sloan, Sidney C. Smith. (2008) 2007 Focused Update of the ACC/AHA 2004 Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction. Journal of the American College of Cardiology 51:2, 210-247
CrossRef139
Gilead I. Lancaster, Hitender Jain, Stuart W. Zarich. (2008) The Role of Aspirin Resistance in the Treatment of Acute Coronary Syndromes. Clinical Cardiology 31:1, 11-17
CrossRef140
Spencer B. King, Sidney C. Smith, John W. Hirshfeld, Alice K. Jacobs, Douglass A. Morrison, David O. Williams. (2008) 2007 Focused Update of the ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention. Journal of the American College of Cardiology 51:2, 172-209
CrossRef141
Miloje Tomasevic, Tomislav Kostic, Svetlana Apostolovic, Zoran Perisic, Danijela Djordjevic-Radojkovic, Goran Koracevic, Sonja Salinger-Martinovic. (2008) Comparative effect of streptokinase and alteplase on electrocardiogram and angiogram signs of myocardial reperfusion in ST segment elevation acute myocardial infarction. Srpski arhiv za celokupno lekarstvo 136:9-10, 481-487
CrossRef142
S. Middeldorp. (2008) Heparin: From animal organ extract to designer drug. Thrombosis Research 122:6, 753-762
CrossRef143
(2008) 2007 Focused update of the ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention. Catheterization and Cardiovascular Interventions 71:1, E1-E40
CrossRef144
Natalie J Carter, Paul L McCormack, Greg L Plosker. (2008) Enoxaparin. Drugs 68:5, 691-710
CrossRef145
Xavier Armoiry, Xavier Dode, Éric Bonnefoy, Gilles Aulagner, François Gimenez†, Éric François. 2008. Traitement de l'infarctus du myocarde avec sus-décalage du segment ST. , 127-155.
CrossRef146
Alipio Mangas Rojas, Francisco Gómez Rodríguez. (2007) Tratamiento multifactorial de la arteriosclerosis. Medicina Clínica 129:20, 785-796
CrossRef147
J.-P. Collet, F. Beygui, O. Barthélemy, B. Livarek, G. Montalescot. (2007) Traitement du thrombus dans les syndromes coronaires aigus en salle de cardiologie interventionnelle. Annales de Cardiologie et d'Angéiologie 56:6, 250-256
CrossRef148
M. Cohen, G. Roubin, F. Kuepper. (2007) The challenge of ST-segment elevation myocardial infarction. International Journal of Clinical Practice 61:12, 2079-2092
CrossRef149
Gabriel Tatu-Chiţoiu, Maria Dorobanţu, Cristina Teodorescu, Elvira Craiu, Marius Vintilă, Bogdan Minescu, Daniel Burghină, Sorin Stamate, Luminiţa Serban, Tudor Protopopescu, Monica Dan, Petre Căpraru, Manuela Guran, Oana Istrătescu, Mircea Vlădoianu, Nicoleta Caea. (2007) Accelerated streptokinase in ST-elevation myocardial infarction — a romanian (ASK–ROMANIA) multicenter registry. International Journal of Cardiology 122:3, 216-223
CrossRef150
Daniel E Hilleman, James P Tsikouris, A. Allen Seals, Jonathan D Marmur. (2007) Fibrinolytic Agents for the Management of ST-Segment Elevation Myocardial Infarction. Pharmacotherapy 27:11, 1558-1570
CrossRef151
H.R. Arntz. (2007) Frühe Antiplättchentherapie und Gerinnungshemmung bei akutem Koronarsyndrom. Notfall + Rettungsmedizin 10:7, 500-510
CrossRef152
Jean-Pierre Bassand, Isabelle Richard-Lordereau, Yves Cadroy. (2007) Efficacy and safety of fondaparinux in patients with acute coronary syndromes. Expert Review of Cardiovascular Therapy 5:6, 1013-1026
CrossRef153
Debabrata Mukherjee, Kim A. Eagle. (2007) The Use of Antithrombotics for Acute Coronary Syndromes in the Emergency Department: Considerations and Impact. Progress in Cardiovascular Diseases 50:3, 167-180
CrossRef154
Michael Kindermann, Oliver Adam, Nikos Werner, Michael Böhm. (2007) Clinical Trial Updates and Hotline Sessions presented at the European Society of Cardiology Congress 2007. Clinical Research in Cardiology 96:11, 767-786
CrossRef155
Christian T. Ruff, Stephen D. Wiviott, David A. Morrow, Satishkumar Mohanavelu, Sabina A. Murphy, Elliott M. Antman, Eugene Braunwald. (2007) TIMI Risk Index and the Benefit of Enoxaparin in Patients with ST-Elevation Myocardial Infarction. The American Journal of Medicine 120:11, 993-998
CrossRef156
Amrita M. Karve, Eduardo Bossone, Rajendra H. Mehta. (2007) Acute ST-Segment Elevation Myocardial Infarction: Critical Care Perspective. Critical Care Clinics 23:4, 685-707
CrossRef157
Jeffrey J. Link, John J. Warner, James A. Lemos. (2007) Low-molecular-weight heparin use in acute coronary syndromes and percutaneous coronary interventions: An update. Current Cardiovascular Risk Reports 1:4, 303-309
CrossRef158
William E. Boden, Kim Eagle, Christopher B. Granger. (2007) Reperfusion Strategies in Acute ST-Segment Elevation Myocardial Infarction. Journal of the American College of Cardiology 50:10, 917-929
CrossRef159
Nick Castle, Crispin Porter, Beverley Thompson. (2007) Acute myocardial infarction complicated by ventricular standstill terminated by thrombolysis and transcutaneous pacing. Resuscitation 74:3, 559-562
CrossRef160
Ruvin S Gabriel, Harvey D White. (2007) ExTRACT-TIMI 25 trial: clarifying the role of enoxaparin in patients with ST-elevation myocardial infarction receiving fibrinolysis. Expert Review of Cardiovascular Therapy 5:5, 851-857
CrossRef161
Robert C. Welsh, Phillip Gordon, Cynthia M. Westerhout, Christopher E. Buller, Blair O'Neill, Paul W. Armstrong. (2007) A novel enoxaparin regime for ST elevation myocardial infarction patients undergoing primary percutaneous coronary intervention: A WEST sub-study. Catheterization and Cardiovascular Interventions 70:3, 341-348
CrossRef162
Vincent E. Friedewald, Eric R. Bates, Christopher B. Granger, Salim Yusuf, William C. Roberts. (2007) The Editor's Roundtable: Arterial Thrombosis and Acute Coronary Syndromes. The American Journal of Cardiology 100:6, 974-980
CrossRef163
Jeffrey L. Anderson, Cynthia D. Adams, Elliott M. Antman, Charles R. Bridges, Robert M. Califf, Donald E. Casey, William E. Chavey, Francis M. Fesmire, Judith S. Hochman, Thomas N. Levin, A. Michael Lincoff, Eric D. Peterson, Pierre Theroux, Nanette Kass Wenger, R. Scott Wright, Sidney C. Smith, Alice K. Jacobs, Cynthia D. Adams, Jeffrey L. Anderson, Elliott M. Antman, Jonathan L. Halperin, Sharon A. Hunt, Harlan M. Krumholz, Frederick G. Kushner, Bruce W. Lytle, Rick Nishimura, Joseph P. Ornato, Richard L. Page, Barbara Riegel. (2007) ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non–ST-Elevation Myocardial Infarction. Journal of the American College of Cardiology 50:7, e1-e157
CrossRef164
E. V. Gelfand, C. P. Cannon. (2007) Myocardial infarction: contemporary management strategies. Journal of Internal Medicine 262:1, 59-77
CrossRef165
Eugene Braunwald. (2007) Reducing Myocardial Injury by Minimizing Imbalance between Oxygen Supply and Demand. Anesthesiology 107:1, 161-163
CrossRef166
Eric R. Bates. (2007) New anticoagulant options for ST-elevation myocardial infarction and unstable angina pectoris/non-ST-elevation myocardial infarction. Current Cardiology Reports 9:4, 289-297
CrossRef167
Thomas J. Kiernan, Bernard J. Gersh. (2007) Thrombolysis in Acute Myocardial Infarction: Current Status. Medical Clinics of North America 91:4, 617-637
CrossRef168
Saumil R. Shah, Claudia P. Hochberg, Duane S. Pinto, C. Michael Gibson. (2007) Reperfusion strategies for ST-elevation myocardial infarction. Current Cardiology Reports 9:4, 281-288
CrossRef169
Richard J. Gumina. (2007) New Trials and Therapies for Acute Myocardial Infarction. Medical Clinics of North America 91:4, 729-749
CrossRef170
Steven R. Steinhubl, Adnan Kastrati, Peter B. Berger. (2007) Variation in the definitions of bleeding in clinical trials of patients with acute coronary syndromes and undergoing percutaneous coronary interventions and its impact on the apparent safety of antithrombotic drugs. American Heart Journal 154:1, 3-11
CrossRef171
Benjamin A. Steinberg, Nazanin Moghbeli, Jacqueline Buros, Mikhail Ruda, Alexander Parkhomenko, B. Soma Raju, Armando García-Castillo, Marianna Janion, José C. Nicolau, Keith A.A. Fox, David A. Morrow, C. Michael Gibson, Elliott M. Antman. (2007) Global outcomes of ST-elevation myocardial infarction: Comparisons of the Enoxaparin and Thrombolysis Reperfusion for Acute Myocardial Infarction Treatment-Thrombolysis In Myocardial Infarction study 25 (ExTRACT-TIMI 25) registry and trial. American Heart Journal 154:1, 54-61
CrossRef172
C. Michael Gibson, Sabina A. Murphy, Gilles Montalescot, David A. Morrow, Diego Ardissino, Marc Cohen, Dietrich C. Gulba, Oscar H. Kracoff, Basil S. Lewis, Nathan Roguin, Elliott M. Antman, Eugene Braunwald. (2007) Percutaneous Coronary Intervention in Patients Receiving Enoxaparin or Unfractionated Heparin After Fibrinolytic Therapy for ST-Segment Elevation Myocardial Infarction in the ExTRACT-TIMI 25 Trial. Journal of the American College of Cardiology 49:23, 2238-2246
CrossRef173
Mark J. Eisenberg. (2007) Substitution of Fractionated for Unfractionated Heparin During High-Risk Percutaneous Coronary Intervention. Journal of the American College of Cardiology 49:23, 2247-2248
CrossRef174
David Fitchett. (2007) The impact of bleeding in patients with acute coronary syndromes: How to optimize the benefits of treatment and minimize the risk. Canadian Journal of Cardiology 23:8, 663-671
CrossRef175
Keith A.A. Fox, Elliott M. Antman, Gilles Montalescot, Stefan Agewall, Bhupathi SomaRaju, Freek W.A. Verheugt, Jose Lopez-Sendon, Hanoch Hod, Sabina A. Murphy, Eugene Braunwald. (2007) The Impact of Renal Dysfunction on Outcomes in the ExTRACT-TIMI 25 Trial. Journal of the American College of Cardiology 49:23, 2249-2255
CrossRef176
Marc S. Sabatine, David A. Morrow, Anthony Dalby, Mathias Pfisterer, Tibor Duris, Jose Lopez-Sendon, Sabina A. Murphy, Runlin Gao, Elliott M. Antman, Eugene Braunwald. (2007) Efficacy and Safety of Enoxaparin Versus Unfractionated Heparin in Patients With ST-Segment Elevation Myocardial Infarction Also Treated With Clopidogrel. Journal of the American College of Cardiology 49:23, 2256-2263
CrossRef177
Sinjin Lee, C Michael Gibson. (2007) Enoxaparin in acute coronary syndromes. Expert Review of Cardiovascular Therapy 5:3, 387-399
CrossRef178
Eric R Bates. (2007) Anticoagulant therapy in acute coronary syndromes. Future Cardiology 3:3, 301-308
CrossRef179
Andrew J Lucking, David E Newby. (2007) Pharmacological antithrombotic adjuncts to percutaneous coronary intervention. Expert Opinion on Pharmacotherapy 8:6, 759-776
CrossRef180
Jonathan D. Rich, John M. Maraganore, Edward Young, Rosa-Maria Lidon, Burt Adelman, Paul Bourdon, Supoat Charenkavanich, Jack Hirsh, Pierre Theroux, Christopher P. Cannon. (2007) Heparin resistance in acute coronary syndromes. Journal of Thrombosis and Thrombolysis 23:2, 93-100
CrossRef181
Mohsin Farooq, Amer S Qureshi, Iain B Squire. (2007) Early management of ST elevation myocardial infarction: a review of practice. Expert Opinion on Pharmacotherapy 8:4, 401-413
CrossRef182
W. Frank Peacock, Judd E. Hollander, Richard W. Smalling, Michael J. Bresler. (2007) Reperfusion strategies in the emergency treatment of ST-segment elevation myocardial infarction. The American Journal of Emergency Medicine 25:3, 353-366
CrossRef183
Nebojsa Despotovic, Goran Loncar, Maja Nikolic-Despotovic, Marjan Ilic, Sinisa Dimkovic. (2007) The safety of enoxaparine use in elderly with acute myocardial infarction. Vojnosanitetski pregled 64:10, 655-658
CrossRef184
(2007) Invited Synopses. Acute Cardiac Care 9:3, 134-174
CrossRef185
Zenon S Kyriakides, Spyros Kourouklis, Konstantinos Kontaras. (2007) Acute Coronary Syndromes in the Elderly. Drugs & Aging 24:11, 901-912
CrossRef186
Marc A. Pfeffer. 2007. Myocardial Infarction: Risks and Hope. , 211-217.
CrossRef187
S.L. Werner. (2007) Enoxaparin versus Unfractionated Heparin with Fibrinolysis for ST-Elevation Myocardial Infarction. Yearbook of Emergency Medicine 2007, 60-61
CrossRef188
Xavier García-Moll, Alfredo Bardají, Joaquín Alonso, Héctor Bueno. (2007) Actualización en cardiopatía isquémica 2006. Revista Española de Cardiología 60, 3-18
CrossRef189
W.H. Frishman. (2007) Enoxaparin versus Unfractionated Heparin with Fibrinolysis for ST-Elevation Myocardial Infarction. Yearbook of Medicine 2007, 321-323
CrossRef190
Danijela Djordjevic-Radojkovic, Zoran Perisic, Miloje Tomasevic, Milan Pavlovic, Svetlana Apostolovic, Ruzica Jankovic, Miodrag Damjanovic, Sonja Salinger-Martinovic, Nenad Bozinovic, Dusan Milenkovic. (2007) Influence of the double antiplatelet therapy on patency of the infarct related artery after acute myocardial infarction with ST-segment elevation. Vojnosanitetski pregled 64:2, 117-121
CrossRef191
Nebojsa Despotovic, Predrag Erceg, Maja Nikolic-Despotovic, Dragoslav P Milosevic, Mladen Davidovic. (2007) Bleeding During Enoxaparin Treatment More Common with Age Over 75 Years and Severe Renal Insufficiency. Drugs & Aging 24:9, 777-779
CrossRef192
Richard C. Becker. 2007. Hemostatic Aspects of Cardiovascular Medicine. , 339-369.
CrossRef193
Alexander GG Turpie. (2006) Fondaparinux in the management of patients with ST-elevation acute myocardial infarction. Vascular Health and Risk Management 2:4, 371-378
CrossRef194
Christopher P. Cannon, Deepak L. Bhatt. (2006) Clinical Trials Update from the Annual Scientific Session of the American College of Cardiology 2006. The American Journal of Cardiology 98:12, S36-S41
CrossRef195
Jean-Philippe Collet, Gilles Montalescot. (2006) Does severe renal insufficiency increase the risk of bleeding after administration of low-molecular-weight heparin?. Nature Clinical Practice Nephrology 2:11, 616-617
CrossRef196
V. Wenzel, S. Russo, H. R. Arntz, J. Bahr, M. A. Baubin, B. W. Böttiger, B. Dirks, V. Dörges, C. Eich, M. Fischer, B. Wolcke, S. Schwab, W. G. Voelckel, H. W. Gervais. (2006) Die neuen Reanimationsleitlinien 2005 des European Resuscitation Council. Der Anaesthesist 55:9, 958-979
CrossRef197
Pierre Théroux, Benoît Labarthe. (2006) Coping with new challenges in acute coronary syndromes. Canadian Journal of Cardiology 22, 13C-20C
CrossRef198
(2006) Enoxaparin versus Unfractionated Heparin in ST-Elevation Myocardial Infarction. New England Journal of Medicine 354:26, 2830-2832
Full Text199
A Michael Lincoff. (2006) How do unfractionated and low-molecular-weight heparin compare after ST-segment elevation MI?. Nature Clinical Practice Cardiovascular Medicine 3:6, 300-301
CrossRef200
John A. Ambrose. (2006) Myocardial Ischemia and Infarction. Journal of the American College of Cardiology 47:11, D13-D17
CrossRef201
Howard C. Herrmann. (2006) Update and rationale for ongoing acute myocardial infarction trials: Combination therapy, facilitation, and myocardial preservation. American Heart Journal 151:6, S30-S39
CrossRef202
Lagakos, Stephen W., . (2006) The Challenge of Subgroup Analyses — Reporting without Distorting. New England Journal of Medicine 354:16, 1667-1669
Full Text203
Gibbons, Raymond J., Fuster, Valentin, . (2006) Therapy for Patients with Acute Coronary Syndromes — New Opportunities. New England Journal of Medicine 354:14, 1524-1527
Full Text
- Letters
